



National Comprehensive
Cancer Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Anal Carcinoma

Version 4.2025 — May 30, 2025

NCCN.org

NCCN recognizes the importance of clinical trials and encourages participation when applicable and available.
Trials should be designed to maximize inclusiveness and broad representative enrollment.

NCCN Guidelines for Patients® available at www.nccn.org/patients

Continue



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 4.2025

Anal Carcinoma

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

***Al B. Benson, III, MD/Chair †**
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

***Alan P. Venook, MD/Vice-Chair † ‡**
UCSF Helen Diller Family
Comprehensive Cancer Center

Mohamed Adam, MD ¶
UCSF Helen Diller Family
Comprehensive Cancer Center

George J. Chang, MD, MS, MHCM ¶
The University of Texas MD Anderson Cancer Center

Yi-Jen Chen, MD, PhD §
City of Hope National Medical Center

Kristen K. Ciombor, MD †
Vanderbilt-Ingram Cancer Center

Madison Conces, MD ‡ †
Case Comprehensive Cancer Center/University
Hospitals Seidman Cancer Center and Cleveland
Clinic Taussig Cancer Institute

Stacey A. Cohen, MD †
Fred Hutchinson Cancer Center

Harry S. Cooper, MD ≠
Fox Chase Cancer Center

Dustin Deming, MD †
University of Wisconsin Carbone Cancer Center

Ignacio Garrido-Laguna, MD, PhD †
Huntsman Cancer Institute
at the University of Utah

Jean L. Grem, MD †
Fred & Pamela Buffett Cancer Center

Carla Harmath, MD ¶
The UChicago Medicine
Comprehensive Cancer Center

Paul Haste, MD ¶
Indiana University Melvin and Bren Simon
Comprehensive Cancer Center

J. Randolph Hecht, MD †
UCLA Jonsson Comprehensive Cancer Center

J. Kevin Hicks, PharmD, PhD, FCCP Σ
Moffitt Cancer Center

Sarah Hoffe, MD §
Moffitt Cancer Center

Steven Hunt, MD ¶
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

Hisham Hussan, MD ≠
UC Davis Comprehensive Cancer Center

Kimberly L. Johung, MD, PhD §
Yale Cancer Center/Smilow Cancer Hospital

***Nora Joseph, MD ≠**
University of Michigan Rogel Cancer Center

Natalie Kirilcuk, MD ¶
Stanford Cancer Institute

Smitha Krishnamurthi, MD †
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center and
Cleveland Clinic Taussig Cancer Institute

Midhun Malla, MD, MS †
O'Neal Comprehensive Cancer Center at UAB

Jennifer K. Maratt, MD, MS ≠
Indiana University Melvin and Bren Simon
Comprehensive Cancer Center

Wells A. Messersmith, MD †
University of Colorado Cancer Center

Jeffrey Meyer, MD, MS §
Johns Hopkins Kimmel Cancer Center

Jeffrey Meyerhardt, MD, MPH †
Dana-Farber Brigham and
Women's Cancer Center

Eric D. Miller, MD, PhD §
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Mary F. Mulcahy, MD ‡ †
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Steven Nurkin, MD, MS ¶
Roswell Park Comprehensive Cancer Center

Hitendra Patel, MD †
UC San Diego Moores Cancer Center

Katrina Pedersen, MD, MS †
Mayo Clinic Comprehensive Cancer Center

Leonard Saltz, MD † ‡ ¶
Memorial Sloan Kettering Cancer Center

Charles Schneider, MD †
Abramson Cancer Center
at the University of Pennsylvania

David Shibata, MD ¶
The University of Tennessee
Health Science Center

Benjamin Shogan, MD ¶
The UChicago Medicine
Comprehensive Cancer Center

Laurie Singer ¥
DoubleLL Productions

Constantinos T. Sofocleous, MD, PhD ¶
Memorial Sloan Kettering Cancer Center

Anna Tavakkoli, MD, MSc ≠
UT Southwestern Simmons
Comprehensive Cancer Center

Christopher G. Willett, MD §
Duke Cancer Institute

Christina Wu, MD †
Mayo Clinic Comprehensive Cancer Center

NCCN
Faviolla Baez-Cruz, PhD
Lisa Gurski, PhD
Frankie Jones

¶ Diagnostic/Interventional radiology	¥ Patient advocacy
≠ Gastroenterology	Σ Pharmacology/Pharmacy
‡ Hematology/Hematology oncology	§ Radiotherapy/Radiation oncology
¶ Internal medicine	¶ Surgery/Surgical oncology
† Medical oncology	* Discussion Section Writing Committee
≠ Pathology	

Continue

[NCCN Guidelines Panel Disclosures](#)



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 4.2025

Anal Carcinoma

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)

[NCCN Anal Carcinoma Panel Members](#)

[Summary of the Guidelines Updates](#)

[Workup and Treatment - Anal Canal Cancer \(ANAL-1\)](#)

[Workup and Treatment - Perianal Cancer \(ANAL-2\)](#)

[Follow-up Therapy and Surveillance \(ANAL-3\)](#)

[Principles of Surgery \(ANAL-A\)](#)

[Principles of Systemic Therapy \(ANAL-B\)](#)

[Principles of Radiation Therapy \(ANAL-C\)](#)

[Principles of Survivorship \(ANAL-D\)](#)

[Staging \(ST-1\)](#)

[Abbreviations \(ABBR-1\)](#)

Find an NCCN Member Institution:
<https://www.nccn.org/home/member-institutions>.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

NCCN Categories of Preference: All recommendations are considered appropriate.

See [NCCN Categories of Preference](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2025.



Updates in Version 4.2025 of the NCCN Guidelines for Anal Carcinoma from Version 3.2025 include:

[ANAL-B 2 of 5](#)

- Principles of Systemic Therapy- Metastatic Cancer

- ▶ First-Line Therapy

- ◊ Carboplatin + paclitaxel + retifanlimab-dlwr: Category and preference changed from category 2B, Other Recommended Regimen to category 2A, Preferred Regimen

- ◊ Carboplatin + paclitaxel: Preference changed from Preferred Regimen to Other Recommended Regimen

[MS-1](#)

- The Discussion section has been updated to reflect the changes in the algorithm.

Updates in Version 3.2025 of the NCCN Guidelines for Anal Carcinoma from Version 2.2025 include:

[ANAL-1](#)

- Workup

- ▶ Footnote c added: Testing for DPYD genetic variants should be considered prior to fluoropyrimidine therapy. After discussions regarding risk assessment, patients may choose DPYD genetic testing. However, no specific test is recommended at this time and there are insufficient data to inform dose adjustments for many of the DPYD variants. See DPYD Testing and Fluoropyrimidine-Associated Toxicity Discussion section in the NCCN Guidelines for Colon Cancer for more information. (Also for ANAL-2)

Updates in Version 2.2025 of the NCCN Guidelines for Anal Carcinoma from Version 1.2025 include:

[ANAL-B 2 of 5](#)

- Footnote c added: Nivolumab and hyaluronidase-nvhy subcutaneous injection may be substituted for IV nivolumab. Nivolumab and hyaluronidase-nvhy has different dosing and administration instructions compared to IV nivolumab. This applies to all areas of the Guideline where nivolumab is listed.

[ANAL-C 5 of 5](#)

- Quality Assurance and Image-Guided Treatment Delivery

- ▶ Sub-bullet 3, language modified: If it is not possible to achieve the dosimetric goals in Table 2, small bowel max point dose should be limited to Dmax 55 Gy, V45 should be ≤150 cc for a bowel bag avoidance structure, and V50 should be ≤30 cc for individual small bowel loops.

[Continued](#)



Updates in Version 1.2025 of the NCCN Guidelines for Anal Carcinoma from Version 1.2024 include:

[ANAL-1](#)

- Workup
 - ▶ Bullet 5 revised: Consider FDG-positron emission tomography (PET)/CT or FDG-PET/MRI (if available) (Also for bullet 3, sub-bullet 1 on ANAL-2)

[ANAL-3](#)

- Footnote o modified: Consider the use of immunotherapy (nivolumab, pembrolizumab, or retifanlimab-dlwr, *cemiplimab-rwlc*, *dostarlimab-gxly*, *tislelizumab-jsgr*, or *toripalimab-tpzi*) (category 2B) before proceeding to APR. Institutional experience has demonstrated that some patients receive a good response and can avoid surgery. (Also for ANAL-4)

[ANAL-B 2 of 5](#)

- Principles of Systemic Therapy- Metastatic Cancer
 - ▶ Tables have been revised and reformatted
 - ▶ First-Line Therapy
 - ◇ Other Recommended Regimens
 - Carboplatin + paclitaxel + retifanlimab-dlwr added as a category 2B recommendation
 - ▶ Second-Line and Subsequent Therapy
 - ◇ Preferred Regimens (if no prior immunotherapy received)
 - The following immunotherapy agents have been added:
 - Cemiplimab-rwlc
 - Dostarlimab-gxly
 - Tislelizumab-jsgr
 - Toripalimab-tpzi

[ANAL-B 3 of 5](#)

- Regimens and dosing updated.

[ANAL-B 4 of 5](#)

- References updated.

[ANAL-C 2 of 5](#)

- Principles of Radiation Therapy
 - ▶ Treatment Information (continued)
 - ◇ Target Volume Definition
 - Sub-bullet 4 modified: To define the gross disease CTV around involved nodes, a 0.5- to 1-cm expansion should be made...


[ANAL-C 5 of 5](#)

- Treatment Information (continued)
 - ▶ Quality Assurance and Image-Guided Treatment Delivery
 - ◇ Sub-bullet 3 revised: If it is not possible to achieve the dosimetric goals in Table 2, small bowel max point dose should be limited to 50 *D*_{max} 55 Gy, V45 should be <495 ≤150 cc for a bowel bag avoidance structure, and V45 50 should be <420 ≤30 cc for individual small bowel loops.
 - Reference added: Alvarez JA, Shi Q, Dasari A, et al. Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. Supplement 2. Protocol update to Alliance A022104. BMC Cancer 2024;24:901.



NCCN Guidelines Version 4.2025

Anal Carcinoma



^a The superior border of the functional anal canal, separating it from the rectum, has been defined as the palpable upper border of the anal sphincter and puborectalis muscles of the anorectal ring. It is approximately 3 to 5 cm in length, and its inferior border starts at the anal verge, the lowermost edge of the sphincter muscles, corresponding to the introitus of the anal orifice.

^b For melanoma histology, see the [NCCN Guidelines for Melanoma: Cutaneous](#); for adenocarcinoma, see the [NCCN Guidelines for Rectal Cancer](#).

^c Testing for *DPYD* genetic variants should be considered prior to fluoropyrimidine therapy. After discussions regarding risk assessment, patients may choose *DPYD* genetic testing. However, no specific test is recommended at this time and there are insufficient data to inform dose adjustments for many of the *DPYD* variants. See *DPYD* Testing and Fluoropyrimidine-Associated Toxicity Discussion section in the [NCCN Guidelines for Colon Cancer](#) for more information.

^d CT should be with IV and oral contrast. Pelvis MRI with contrast. If intravenous iodinated contrast material is contraindicated due to significant contrast allergy or renal failure, then MRI examination of the abdomen and pelvis with IV gadolinium-based contrast agent (GBCA) can be obtained in select patients (see American College of Radiology contrast manual: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf). Intravenous contrast is not required for the chest CT.

^e FDG-PET/CT scan does not replace a diagnostic CT. FDG-PET/CT performed skull base to mid-thigh.

^f [Principles of Surgery \(ANAL-A\)](#).

^g Para-aortic nodes that can be included in a radiation field.

^h Modifications to cancer treatment should not be made solely based on HIV status. [See NCCN Guidelines for Cancer in People with HIV](#).

ⁱ [Principles of Systemic Therapy \(ANAL-B\)](#).

^j [Principles of Radiation Therapy \(ANAL-C\)](#).

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 4.2025


Anal Carcinoma

CLINICAL PRESENTATION

WORKUP^c

CLINICAL STAGE

PRIMARY TREATMENT^h



^b For melanoma histology, see the [NCCN Guidelines for Melanoma: Cutaneous](#); for adenocarcinoma, see the [NCCN Guidelines for Rectal Cancer](#).

^c Testing for *DPYD* genetic variants should be considered prior to fluoropyrimidine therapy. After discussions regarding risk assessment, patients may choose *DPYD* genetic testing. However, no specific test is recommended at this time and there are insufficient data to inform dose adjustments for many of the *DPYD* variants. See *DPYD* Testing and Fluoropyrimidine-Associated Toxicity Discussion section in the [NCCN Guidelines for Colon Cancer](#) for more information.

^d CT should be with IV and oral contrast. Pelvis MRI with contrast. If intravenous iodinated contrast material is contraindicated due to significant contrast allergy or renal failure, then MRI examination of the abdomen and pelvis with IV GBCA can be obtained in select patients (see American College of Radiology contrast manual: https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf). Intravenous contrast is not required for the chest CT.

^e FDG-PET/CT scan does not replace a diagnostic CT. FDG-PET/CT performed skull base to mid-thigh.

^f [Principles of Surgery \(ANAL-A\)](#).

^g Para-aortic nodes that can be included in a radiation field.


^h Modifications to cancer treatment should not be made solely based on HIV status. See [NCCN Guidelines for Cancer in People with HIV](#).

ⁱ [Principles of Systemic Therapy \(ANAL-B\)](#).

^j [Principles of Radiation Therapy \(ANAL-C\)](#).

^k The perianal region starts at the anal verge and includes the perianal skin over a 5-cm radius from the squamous mucocutaneous junction.

Note: All recommendations are category 2A unless otherwise indicated.



^f [Principles of Surgery \(ANAL-A\)](#).

ⁱ [Principles of Systemic Therapy \(ANAL-B\)](#).

^j [Principles of Radiation Therapy \(ANAL-C\)](#).

^l Based on the results of the ACT-II study, it may be appropriate to follow patients who have not achieved a complete clinical response with persistent anal cancer up to 6 months following completion of RT and chemotherapy as long as there is no evidence of progressive disease during this period of follow-up. Persistent disease may continue to regress even at 26 weeks from the start of treatment. James RD, et al. Lancet Oncol 2013;14:516-524.


^m Palliative RT may be considered in symptomatic patients. Records of previous RT should be carefully reviewed and considered prior to potential re-irradiation of previously irradiated fields. See [Principles of Radiation Therapy \(ANAL-C\)](#).

ⁿ Consider muscle flap reconstruction.

^o [Principles of Survivorship \(ANAL-D\)](#).

^p Consider the use of immunotherapy (nivolumab, pembrolizumab, retifanlimab-dlwr, cemiplimab-rwlc, dostarlimab-gxly, tislelizumab-jsgr, or toripalimab-tpzi) (category 2B) before proceeding to APR. Institutional experience has demonstrated that some patients receive a good response and can avoid surgery.

Note: All recommendations are category 2A unless otherwise indicated.



^l Based on the results of the ACT-II study, it may be appropriate to follow patients who have not achieved a complete clinical response with persistent anal cancer up to 6 months following completion of RT and chemotherapy as long as there is no evidence of progressive disease during this period of follow-up. Persistent disease may continue to regress even at 26 weeks from the start of treatment. James RD, et al. Lancet Oncol 2013;14:516-524.

^m Palliative RT may be considered in symptomatic patients. Records of previous RT should be carefully reviewed and considered prior to potential re-irradiation of previously irradiated fields. See [Principles of Radiation Therapy \(ANAL-C\)](#).

ⁿ Consider muscle flap reconstruction.

^o [Principles of Survivorship \(ANAL-D\)](#).

^p Consider the use of immunotherapy (nivolumab, pembrolizumab, retifanlimab-dlwr, cemiplimab-rwlc, dostarlimab-gxly, tislelizumab-jsgr, or toripalimab-tpzi) (category 2B) before proceeding to APR. Institutional experience has demonstrated that some patients receive a good response and can avoid surgery.

^q Use imaging studies as per initial workup.

Note: All recommendations are category 2A unless otherwise indicated.



PRINCIPLES OF SURGERY

Local Excision

- **Superficially Invasive Squamous Cell Carcinoma (SISCCA)**
 - ▶ SISCCA are anal cancers that are generally found incidentally in the setting of a biopsy or excision of what is thought to be a benign lesion such as a condyloma, hemorrhoid, or anal skin tag.
 - ▶ For such lesions that are noted to have histologically negative margins in carefully selected patients followed by an experienced provider and/or team, local excision alone with a structured surveillance plan may represent adequate treatment.
- **Perianal (Anal Margin) Cancer**
 - ▶ T1N0, moderately to well-differentiated or select T2N0 squamous cell carcinoma (SCC) of the perianal (anal margin) region may be adequately treated by local excision with 1-cm margins.
 - ◊ Local surgical excision of select, early lesions may be considered:
 - Where the tumor forms a discrete lesion arising from the perianal skin that is clearly separate from the anal canal
 - Where negative margin excision can be accomplished without compromise of the adjacent sphincter muscles
 - Where there is no evidence of regional nodal involvement

Radical Surgery

- **Local Recurrence/Persistence**
 - ▶ APR is the primary treatment.
 - ▶ General principles for APR are similar to those for distal rectal cancer and include the incorporation of total mesorectal excision (TME).
 - ▶ APR for anal cancer may require wider lateral perianal margins.
 - ▶ Due to the necessary exposure of the perineum to radiation, patients are prone to poor perineal wound healing and may benefit from the use of reconstructive tissue flaps for the perineum such as the vertical rectus or local myocutaneous flaps.
- **Inguinal Recurrence**
 - ▶ Patients who have already received groin radiation should undergo an inguinal node dissection.
 - ▶ Groin dissection can be done with or without APR depending on whether disease is isolated to the groin or is in conjunction with recurrence/persistence at the primary site.

Note: All recommendations are category 2A unless otherwise indicated.



PRINCIPLES OF SYSTEMIC THERAPY – LOCALIZED CANCER

Chemo/RT for Localized Cancer	
<u>Preferred Regimens</u>	<u>Other Recommended Regimens</u>
<ul style="list-style-type: none"> • 5-FU + mitomycin + RT • Capecitabine + mitomycin + RT 	<ul style="list-style-type: none"> • 5-FU + cisplatin + RT (category 2B)

Systemic Therapy Regimens and Dosing – Localized Cancer

- 5-FU + mitomycin + RT^{1,2}
 - ▶ Continuous infusion 5-FU 1000 mg/m²/day IV days 1–4 and 29–32
 Mitomycin 10 mg/m² IV bolus days 1 and 29 (capped at 20 mg) with RT
 or
 - ▶ Continuous infusion 5-FU 1000 mg/m²/day IV days 1–4 and 29–32
 Mitomycin 12 mg/m² IV bolus day 1 (capped at 20 mg) with RT
- Capecitabine + mitomycin + RT^{3,4}
 - ▶ Capecitabine 825 mg/m² PO BID Monday–Friday, on days of radiation treatment only, throughout the duration of RT (typically 28–30 treatment days)
 Mitomycin 10 mg/m² IV bolus days 1 and 29 (capped at 20 mg) with RT
 or
 - ▶ Capecitabine 825 mg/m² PO BID Monday–Friday, on days of radiation treatment only, throughout the duration of RT (typically 28–30 treatment days)
 Mitomycin 12 mg/m² IV bolus day 1 (capped at 20 mg) with RT
- 5-FU + cisplatin + RT⁵
 - ▶ Cisplatin 75 mg/m² IV day 1
 Continuous infusion 5-FU 1000 mg/m²/day IV days 1–4
 Repeat every 4 weeks with RT

[References on ANAL-B 4 of 5](#)

Note: All recommendations are category 2A unless otherwise indicated.



NCCN Guidelines Version 4.2025

Anal Carcinoma

PRINCIPLES OF SYSTEMIC THERAPY – METASTATIC CANCER^a

First-Line Therapy		Chemo/RT to the Primary Site for Local Control
<u>Preferred Regimens</u> <ul style="list-style-type: none"> • Carboplatin + paclitaxel + retifanlimab-dlwr^a 	<u>Other Recommended Regimens</u> <ul style="list-style-type: none"> • Carboplatin + paclitaxel • FOLFCIS • mFOLFOX6^b • 5-FU + cisplatin (category 2B) • Modified docetaxel/cisplatin/fluorouracil (DCF) (category 2B) 	<ul style="list-style-type: none"> • 5-FU + RT • Capecitabine + RT

Second-Line and Subsequent Therapy	
<u>Preferred Regimens</u> (if no prior immunotherapy received) ^a <ul style="list-style-type: none"> • Cemiplimab-rwlc • Dostarlimab-gxly • Nivolumab^c • Pembrolizumab • Retifanlimab-dlwr • Tislelizumab-jsgr • Toripalimab-tpzi 	<u>Other Recommended Regimens</u> (if not previously given) <ul style="list-style-type: none"> • Carboplatin + paclitaxel • FOLFCIS • mFOLFOX6^b • 5-FU + cisplatin (category 2B) • Modified DCF (category 2B)

[Regimens and Dosing on ANAL-B 3 of 5](#)

^a [NCCN Guidelines for the Management of Immunotherapy-Related Toxicities](#).

^b Discontinuation of oxaliplatin should be strongly considered after 3 to 4 months of therapy (or sooner for unacceptable neurotoxicity) while maintaining other agents until time of progression. Oxaliplatin may be reintroduced if it was discontinued for neurotoxicity rather than for disease progression.

^c Nivolumab and hyaluronidase-nvhy subcutaneous injection may be substituted for IV nivolumab. Nivolumab and hyaluronidase-nvhy has different dosing and administration instructions compared to IV nivolumab. This applies to all areas of the Guideline where nivolumab is listed.

Note: All recommendations are category 2A unless otherwise indicated.



PRINCIPLES OF SYSTEMIC THERAPY – METASTATIC CANCER

Systemic Therapy Regimens and Dosing – Metastatic Cancer

- Carboplatin + paclitaxel
 - ▶ Carboplatin AUC 5 IV day 1
 - Paclitaxel 175 mg/m² IV day 1
 - Repeat every 21 days⁶
 - or
 - ▶ Carboplatin AUC 5 IV day 1
 - Paclitaxel 80 mg/m² IV days 1, 8, 15
 - Repeat every 28 days⁷
- FOLFCIS⁸

Cisplatin 40 mg/m² IV over 30 minutes on day 1*

Leucovorin 400 mg/m² IV day 1*

5-FU 400 mg/m² IV bolus day 1, then 1000 mg/m²/day x 2 days (total 2000 mg/m² over 46–48 hours)

IV continuous infusion

Repeat every 2 weeks

*Cisplatin and leucovorin are given concurrently
- mFOLFOX⁹

Oxaliplatin 85 mg/m² IV day 1

Leucovorin 400 mg/m² IV day 1

5-FU 400 mg/m² IV bolus day 1, then 1200 mg/m²/day x 2 days (total 2400 mg/m² over 46–48 hours)

IV continuous infusion

Repeat every 2 weeks
- 5-FU + cisplatin
 - ▶ Cisplatin 60 mg/m² IV day 1
 - Continuous infusion 5-FU 1000 mg/m²/day IV days 1–4
 - Repeat every 3 weeks¹⁰
 - or
 - ▶ Cisplatin 75 mg/m² IV day 1
 - Continuous infusion 5-FU 750 mg/m²/day IV days 1–5
 - Repeat every 4 weeks¹¹
- Carboplatin + paclitaxel + retifanlimab-dlwr¹²

Carboplatin AUC 5 IV day 1

Paclitaxel 80 mg/m² IV days 1, 8, and 15

Retifanlimab-dlwr 500 mg IV day 1

Repeat every 28 days for 6 cycles

Followed by retifanlimab-dlwr 500 mg IV day 1

Repeat every 28 days for up to 7 cycles
- Modified DCF¹³

Docetaxel 40 mg/m² IV day 1

Cisplatin 40 mg/m² IV day 1

Fluorouracil 1200 mg/m²/day x 2 days (total 2400 mg/m² over 46–48 hours)

Repeat every 2 weeks
- Cemiplimab-rwlc^{14,15}

350 mg IV day 1

Repeat every 3 weeks
- Dostarlimab-gxly¹⁶

Dostarlimab-gxly 500 mg IV every 3 weeks for 4 doses followed by 1000 mg IV every 6 weeks
- Nivolumab¹⁷

Nivolumab 240 mg IV every 2 weeks or Nivolumab 3 mg/kg IV every 2 weeks or Nivolumab 480 mg IV every 4 weeks
- Pembrolizumab¹⁸

Pembrolizumab 200 mg IV every 3 weeks or Pembrolizumab 2 mg/kg IV every 3 weeks or Pembrolizumab 400 mg IV every 6 weeks
- Retifanlimab-dlwr¹⁹

500 mg IV on day 1

Repeat every 4 weeks
- Tislelizumab-jsgr²⁰⁻²³

200 mg IV day 1

Repeat every 3 weeks
- Toripalimab-tpzi^{24,25}

3 mg/kg IV day 1

Repeat every 2 weeks

Chemo/RT

- 5-FU + RT
 - ▶ 5-FU 225 mg/m² IV over 24 hours (continuous infusion) daily on days 1–5 or 1–7 for 5 weeks with RT²⁶⁻²⁸
- Capecitabine + RT
 - ▶ Capecitabine 825 mg/m² PO twice daily Monday–Friday, on days of radiation treatment only, throughout the duration of RT (typically 28–30 treatment days)²⁹⁻³¹

Note: All recommendations are category 2A unless otherwise indicated.

[References on ANAL-B 4 of 5](#)



PRINCIPLES OF SYSTEMIC THERAPY REFERENCES

- ¹ Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA* 2008;299:1914-1921.
- ² James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. *Lancet Oncol* 2013;14:516-524.
- ³ Goodman KA, Julie D, Cercek A, et al. Capecitabine with mitomycin reduces acute hematologic toxicity and treatment delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer. *Int J Radiat Oncol Biol Phys* 2017;98:1087-1095.
- ⁴ Thind G, Johal B, Follwell M, Kennecke HF. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. *Radiat Oncol* 2014;9:124.
- ⁵ Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. *J Clin Oncol* 2012;30:4344-4351.
- ⁶ Kim R, Byer J, Fulp WJ, et al. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. *Oncology* 2014;87:125-132.
- ⁷ Rao S, Sclafani F, Eng C, et al. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAACT. *J Clin Oncol* 2020;38:2510-2518.
- ⁸ Mondaca S, Chatila WK, Bates D, et al. FOLFOX treatment and genomic correlates of response in advanced anal squamous cell cancer. *Clin Colorectal Cancer* 2019;18:e39-e52.
- ⁹ Matsunaga M, Miwa K, Oka Y, et al. Successful treatment of metastatic anal canal adenocarcinoma with mFOLFOX + bevacizumab. *Case Rep Oncol* 2016;9:249-254.
- ¹⁰ Sclafani F, Adams RA, Eng C, et al. InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease. *J Clin Oncol* 2015;33:3_suppl.TPS792.
- ¹¹ Eng C, Chang GJ, You YN, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. *Oncotarget* 2014;5:11133-11142.
- ¹² Rao S, Samalin-Scalzi E, Evesque L, et al. POD1UM-303/InterAACT 2: Phase 3 study of retifanlimab with carboplatin-paclitaxel in patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy [abstract]. *Ann Oncol* 2024;35:S1217.
- ¹³ Kim S, Francois E, Andre T, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. *Lancet Oncol* 2018;19:1094-1106.
- ¹⁴ Paccaly AJ, Migden MR, Papadopoulos KP, et al. Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. *Adv Ther* 2021;38:2365-2378.
- ¹⁵ Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. *Lancet Oncol* 2020;21:294-305.
- ¹⁶ André T, Berton D, Curigliano G, et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors. *JAMA Netw Open* 2023;6:e2341165.
- ¹⁷ Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicenter, single-arm, phase 2 study. *Lancet Oncol* 2017;18:446-453.
- ¹⁸ Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. *Ann Oncol* 2017;28:1036-1041.
- ¹⁹ Rao S, Anandappa G, Capdevila J, et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). *ESMO Open* 2022;7:100529.
- ²⁰ Li J, Xu Y, Zang A, et al. Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors. *Chin J Cancer Res* 2024;36:257-269.
- ²¹ Pang K, Yang Y, Tian D, et al. Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial). *BMJ Open* 2023;13:e069499.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)

ANAL-B
4 OF 5



PRINCIPLES OF SYSTEMIC THERAPY REFERENCES

- ²² Yang Z, Zhang X, Zhang J, et al. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial). *BMC Cancer* 2022;22:462.
- ²³ Zhang L, Geng Z, Hao B, et al. Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. *Cancer Control* 2022;29:10732748221111296.
- ²⁴ Xia F, Wang Y, Wang H, et al. Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH). *J Clin Oncol* 2024;42:3308-3318.
- ²⁵ Chen Y, Wang Y, Zhang H, et al. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E). *BMJ Open* 2023;13:e076048.
- ²⁶ O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. *N Engl J Med* 1994; 331:502-507.
- ²⁷ Rich TA, Ajani JA, Morrison WH, et al. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. *Radiother Oncol* 1993;27:209-215.
- ²⁸ Charnley N, Choudhury A, Chesser P, et al. Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. *Br J Cancer* 2005;92:1221-1225.
- ²⁹ O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. *J Clin Oncol* 2014;32:1927-1934.
- ³⁰ Hofheinz R, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomized, multicentre, non-inferiority, phase 3 trial. *Lancet Oncol* 2012;13:579-588.
- ³¹ Xu WD, Jiang HY, Gao JM, et al. Preliminary results on anal cancer by applying intensity modulated radiotherapy and synchronous capecitabine chemotherapy simultaneously. *Transl Cancer Res* 2020;9:4366-4372.

Note: All recommendations are category 2A unless otherwise indicated.



PRINCIPLES OF RADIATION THERAPY¹

General Principles

- The consensus of the Panel is that intensity-modulated RT (IMRT) is preferred over 3D conformal RT (3D-CRT) in the treatment of anal carcinoma.² IMRT requires expertise and careful target design to avoid reduction in local control by so-called “marginal-miss.”³ The clinical target volumes (CTVs) for anal cancer used in the RTOG-0529 trial have been described in detail.² The outcome results of RTOG-0529 have been reported.⁴ Also see [The RTOG Consensus Panel Contouring Atlas](#) for more details of the contouring atlas defined by RTOG. The information below provides details regarding simulation, target volume definition, dose prescription, organs at risk (OAR), IMRT constraints, quality assurance, and image guidance delivery.
- Image-guided RT (IGRT) with kilovoltage (kV) imaging or cone beam CT imaging should be routinely used during the course of treatment with IMRT and stereotactic body RT (SBRT).
- Consider SBRT for patients with oligometastatic disease.

Treatment Information

• Simulation

- ▶ After clinical and radiologic staging, CT-based simulation is performed for radiation treatment planning. If available, FDG-PET/CT, MRI pelvis, or FDG-PET/MRI (if available) at the time of simulation may be helpful to define local and regional target structures. Patients can be simulated in the supine or prone position and there are benefits to each approach in the appropriate clinical setting. Prone setup with a false tabletop allows for improved small bowel avoidance and may be useful in individuals with a large pannus and pelvic node involvement. Supine setup is usually more reproducible with less setup variability, potentially allowing for reduced planning target volume (PTV) margins and smaller treatment fields. Patients are typically simulated for anal cancer IMRT planning in the supine position with legs slightly abducted (frog-legged) with semi-rigid immobilization in vacuum-locked bag or alpha-cradle. Patients are instructed to maintain a full bladder for simulation and treatment.
- ▶ In males,* the external genitalia are typically positioned inferiorly such that setup is reproducible. In females,* a vaginal dilator can be placed to help delineate the genitalia and move the vulva and lower vagina away from the primary tumor. A radiopaque marker should be placed at the anal verge and perianal skin involvement can be outlined with radio-opaque catheters. It may be helpful to place a catheter with rectal contrast in the anal canal at the time of simulation for tumor delineation.
- ▶ In patients with adequate renal function, IV contrast facilitates identification of the pelvic and groin vasculature (which approximates at-risk nodal regions). Oral contrast identifies small bowel as an avoidance structure during treatment planning. For tumors involving the perianal skin or superficial inguinal nodes, bolus should be placed as necessary for adequate dosing of gross disease in these areas. Routine use of bolus may not be necessary as the tangential effect of IMRT may minimize skin sparing. In situations where adequate dosing of superficial targets is uncertain, in vivo diode dosimetry with the first treatment fraction can ensure appropriate dose at the skin surface.

* NCCN recommendations have been developed to be inclusive of individuals of all sexual and gender identities to the greatest extent possible. On this page, the terms males and females refer to sex assigned at birth.

¹ Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-1921.

² Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74:824-830.

³ Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Canc Netw 2010;8:123-129.

⁴ Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86:27-33.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)

ANAL-C
1 OF 5



PRINCIPLES OF RADIATION THERAPY¹

Treatment Information (continued)

• Target Volume Definition

- ▶ Target volume definition should be performed per ICRU 50 recommendations. Gross tumor volume (GTV) should include all primary tumor and involved lymph nodes, using information from physical examination, endoscopic findings, diagnostic imaging, and simulation planning study for delineation. CTV should include the GTV plus areas at risk for microscopic spread from the primary tumor and at-risk nodal areas. If the primary tumor cannot be determined with available information (such as after local excision), the anal canal may be used as a surrogate target.
- ▶ The pelvic and inguinal nodes should be routinely treated in all patients.
- ▶ When using IMRT, a separate CTV volume for each planned treatment dose tier is contoured. One approach has been to define three tiers: a gross disease only volume, a high-risk elective nodal volume (including gross disease), and low-risk elective nodal volume (including gross disease). These volumes are determined by the presence or absence of tumor based on physical examination, biopsy, diagnostic and planning studies, and risk of nodal spread depending on tumor stage at presentation. The rationale for this approach is based on the shrinking fields technique. In RTOG-0529, a gross disease volume with a single elective nodal volume are used to deliver the prescribed course (dose-painting).
- ▶ In defining the gross disease CTV around the primary tumor, an approximately 1- to 2-cm margin around GTV should be used with manual editing to avoid muscle or bone at low risk for tumor infiltration. To define the gross disease CTV around involved nodes, a 0.5- to 1-cm expansion should be made beyond the contoured involved lymph node with manual editing to exclude areas at low risk for tumor infiltration.
- ▶ At-risk nodal regions include mesorectal, presacral, internal and external iliac, and inguinal nodes. The mesorectal volume encompasses the rectum and surrounding lymphatic tissue. The presacral nodal volume is typically defined as an approximately 1-cm strip over the anterior sacral prominence. To contour the internal and external iliac nodes, it is recommended to generally contour the iliac arteries and veins with approximately 0.7-cm margin (1- to 1.5-cm anteriorly on external iliac vessels) to include adjacent lymph nodes. In order to include the obturator lymph nodes, external and internal iliac volume contours should be joined parallel to the pelvic sidewall. The inguinal node volume extends beyond the external iliac contour along the femoral artery from approximately the upper edge of the superior pubic rami to approximately 2 cm caudad to saphenous/femoral artery junction. The inguinal node volume should be contoured as a compartment with general margins. The medial and lateral borders may be defined by adductor longus and sartorius muscles, respectively. Several recently published atlases are helpful to review when defining elective nodal CTVs.^{5,6} The above descriptions are generalizations and each plan should be individualized based on the anatomy of each patient and tumor distribution.

¹ Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-1921.

⁵ Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiation Oncology Biol Phys 2009;74:824-830.

⁶ Ng M, Leong T, Chander S, et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiation Oncology Biol Phys 2012;83:1455-1462.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)

ANAL-C
2 OF 5



PRINCIPLES OF RADIATION THERAPY¹

Treatment Information (continued)

• Target Volume Definition

- ▶ The high-risk elective nodal volume typically includes the gross disease CTV plus the entire mesorectum, presacral nodes, and bilateral internal and external iliac lymph nodes inferior to the sacroiliac joint. In patients with gross inguinal nodal involvement, the bilateral or unilateral inguinal nodes may be included in the high-risk elective nodal volume. The low-risk elective nodal volume should include the gross disease CTV, high-risk elective nodal CTV, and presacral, bilateral internal, and external iliac nodes above the inferior border of the sacroiliac joint to the bifurcation of the internal and external iliac vessels at approximately L5/S1 vertebral body junction. If there is no obvious involvement of the bilateral inguinal nodes, these are included in the low-risk elective nodal volume.
- ▶ PTV should account for effects of organ and patient movement and inaccuracies in beam and patient setup. PTV expansions should typically be approximately 0.5- to 1.0-cm depending on use of image guidance and physician practice with treatment setup for each defined CTV. To account for differences in bladder and rectal filling, a more generous CTV to PTV margin is applied in these regions. These volumes may be manually edited to limit the borders to the skin surface for treatment planning purposes.

• Dose Prescription

- ▶ With IMRT treatment planning, doses are typically prescribed to PTVs. The dose of radiation required to control disease is extrapolated from historical studies that show excellent rates of control with concurrent radiation and chemotherapy. Typically prescribed dose varies by size of the tumor and risk of microscopic spread in elective nodal areas. One approach with “shrinking field technique” is that the low-risk elective nodal PTV volume is typically prescribed to 30.6 Gy in 1.8 Gy daily fractions. The high-risk elective nodal PTV is sequentially prescribed an additional 14.4 Gy in 1.8 Gy daily fractions for a total prescribed dose of 45 Gy. Finally, for T1–2 lesions with residual disease after 45 Gy, T3–4 lesions, or N1 lesions, an additional 5.4–14.4 Gy in 1.8–2 Gy daily fractions is again sequentially prescribed to the gross disease PTV volume (total dose, 50.4–59.4 Gy).
- ▶ In RTOG-0529, the prescription parameters are different due to the use of only a single elective nodal volume and slightly different dose prescriptions depending on tumor stage. Furthermore, delivery of escalating dose to different target volumes was performed using a simultaneous integrated boost (SIB) dose painting technique with a maximum dose of 1.8 Gy per fraction to the primary tumor and large volume gross nodal involvement and 1.5 Gy per daily fraction to elective nodal areas. Table 1 outlines dose prescriptions by TNM stage according to the RTOG-0529 protocol. The SIB approach offers the convenience of developing a single treatment plan with reduced planning complexity, albeit with a lower biological dose delivered to the elective nodal areas.
- ▶ For patients untreated presenting with synchronous local and metastatic disease, a platinum-based regimen is standard practice, and radiation can be considered for local control. The approach to radiation depends on the patient’s performance status and extent of metastatic disease. If performance status is good and metastatic disease is limited, treat involved fields, 45–54 Gy to the primary tumor and involved sites in the pelvis, in coordination with plans for a platinum-based regimen. If there is low-volume liver oligometastasis, an SBRT dosing schema after systemic therapy may be appropriate depending on response. If metastatic disease is extensive and life expectancy is limited, a different schedule and dose of radiation should be considered, again in coordination with plans for 5-FU/cisplatin or a platinum-based regimen.

¹ Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-1921.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)

ANAL-C
3 OF 5



PRINCIPLES OF RADIATION THERAPY¹

Treatment Information (continued)

Table 1: Dose Specification of Primary and Nodal Planning Target Volumes: RTOG-0529⁴

TNM Stage	Primary Tumor PTV Dose	Involved Nodal PTV Dose	Nodal PTV Dose
T1, N0	50.4 Gy (28 fxs at 1.8 Gy/fx)	N/A	42 Gy (28 fxs at 1.5 Gy/fx)
T2, N0	50.4 Gy (28 fxs at 1.8 Gy/fx)	N/A	42 Gy (28 fxs at 1.5 Gy/fx)
T3–4, N0	54 Gy (30 fxs at 1.8 Gy/fx)	N/A	45 Gy (30 fxs at 1.5 Gy/fx)
T any, N+ (≤3 cm)	54 Gy (30 fxs at 1.8 Gy/fx)	50.4 Gy (30 fxs at 1.68 Gy/fx)	45 Gy (30 fxs at 1.5 Gy/fx)
T any, N+ (>3 cm)	54 Gy (30 fxs at 1.8 Gy/fx)	54 Gy (30 fxs at 1.8 Gy/fx)	45 Gy (30 fxs at 1.5 Gy/fx)

• Dose Prescription

- ▶ The usual scenario of recurrent disease is recurrence in the primary site or nodes after previous RT and chemotherapy. In this setting, surgery should be performed if possible, and, if not, palliative RT and chemotherapy can be considered based on symptoms, extent of recurrence, and prior treatment. RT technique and doses are dependent on dosing and technique of prior treatment. In the setting of pure palliation, doses of 20–25 Gy in 5 fractions to 30 Gy in 10 fractions can be considered. SBRT can also be considered for treatment of primary and nodal recurrence in the setting of low-volume metastatic disease.

• OARs and IMRT Constraints

- ▶ It is important to accurately define OARs so that dose to these structures can be minimized during treatment. In anal cancer, 2D and 3D treatment planning techniques are limited in their ability to spare most pelvic normal tissues due to the location of the target. With IMRT, dose to small bowel, bladder, pelvic/femoral bones, and external genitalia can be sculpted and minimized despite close proximity of these organs to target volumes. When contouring these structures, it is typically best to demarcate normal tissues on axial CT at least 2 cm above and below the PTV. Oral contrast is helpful to delineate the small bowel. While there is significant variability in how to contour the small bowel, one approach entails contouring the entire volume of peritoneal space in which the small bowel can move. As with elective nodal volume delineation, contouring atlases offer excellent guidance on defining OARs.⁷ Once the OARs have been identified, the chief aim of IMRT planning is to limit the dose to these structures without compromising PTV coverage. The extent to which OARs can be avoided largely depends on the location and extent of tumor involvement at presentation as well as the extent to which the bowel extends into the lower pelvis and a given individual's anatomy.
- ▶ Given patient variation with respect to OAR position and areas of tumor involvement, practical dose constraint guidelines are challenging. In tumors without gross nodal involvement it is often possible to limit OAR doses even further. Alternatively, in tumors with gross nodal involvement within the pelvis, compromise of PTV coverage may be necessary to limit doses to normal tissues, such as small bowel. Table 2 outlines dose constraints in RTOG-0529.

¹ Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-1921.

⁴ Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86:27-33.

⁷ Gay HA, Barthold HJ, O'Meara E, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas. Int J Radiation Oncol Biol Phys 2012;83:e353-e362.

Note: All recommendations are category 2A unless otherwise indicated.

[Continued](#)



PRINCIPLES OF RADIATION THERAPY¹

Treatment Information (continued)

Table 2: DP-IMRT Dose Constraints for Normal Tissues⁸

Organ	Dose (Gy) at <5% Volume	Dose (Gy) at <35% Volume	Dose (Gy) at <50% Volume
Small bowel [†]	45 (<20 cc)	35 (<150 cc)	30 (<200 cc)
Femoral heads	44	40	30
Iliac crest	50	40	30
External genitalia	40	30	20
Bladder	50	40	35
Large bowel [†]	45 (<20 cc)	35 (<150 cc)	30 (<200 cc)

Organs are listed in order of decreasing priority.
†Dose constraints are based on absolute volume instead of % volume.

• Quality Assurance and Image-Guided Treatment Delivery

- ▶ Due to the sophistication and complexity of IMRT planning for anal cancer, comprehensive quality assurance measures must be implemented to ensure minimal variability between the designed and delivered treatment plans. Each institution should have a quality assurance program in place for the treatment of patients with anal cancer.
- ▶ The use of image guidance for radiation treatment delivery has significantly improved confidence in daily treatment setup. This has allowed for shrinking CTV to PTV expansions during the treatment planning process, which in turn further minimizes dose to OARs.
- ▶ If it is not possible to achieve the dosimetric goals in Table 2, small bowel max point dose should be limited to Dmax 55 Gy, V45 should be ≤150 cc, and V50 should be ≤30 cc for individual small bowel loops.^{9,10}

• Supportive Care

- ▶ Patients should be considered for vaginal dilators and instructed on the symptoms of vaginal stenosis.
- ▶ Patients of childbearing potential should be counseled about the effects of premature menopause and consideration should be given to referral for discussion of hormone replacement strategies.
- ▶ Patients of childbearing potential should be counseled that an irradiated uterus cannot carry a fetus to term.
- ▶ Patients should be counseled on sexual dysfunction, potential for future low testosterone levels, and infertility risks and given information regarding sperm banking or oocyte, egg, or ovarian tissue banking, as appropriate, prior to treatment.

¹ Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-1921.

⁸ Reprinted from the International Journal of Radiation Oncology, Biology, Physics, Vol. 86/1, Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2013;86:27-33 with permission from Elsevier.

⁹ Kavanagh BD, Pan CC, Dawson LA, et al. Radiation dose-volume effects in the stomach and small bowel. Int J Radiat Oncol Biol Phys 2010;76:S101-107.

¹⁰ Alvarez JA, Shi Q, Dasari A, et al. Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer. Supplement 2. Protocol update to Alliance A022104. BMC Cancer 2024;24:901.

Note: All recommendations are category 2A unless otherwise indicated.



PRINCIPLES OF SURVIVORSHIP

Anal Carcinoma Surveillance:

- Long-term surveillance should be carefully managed with routine good medical care and monitoring, including cancer screening, routine health care, and preventive care.

Survivorship Care Planning:

The oncologist and primary care provider should have defined roles in the surveillance period, with roles communicated to the patient.¹

- Develop survivorship care plan that includes:
 - ▶ Overall summary of treatment, including all surgeries, radiation treatments, and chemotherapy received.
 - ▶ Description of possible expected time to resolution of acute toxicities, long-term effects of treatment, and possible late sequelae of treatment.
 - ▶ Surveillance recommendations.
 - ▶ Delineation of appropriate timing of transfer of care with specific responsibilities identified for primary care physician and oncologist.
 - ▶ Health behavior recommendations.
 - ▶ Fertility counseling.

Management of Late/Long-term Sequelae of Disease or Treatment²⁻⁶:

- For issues related to distress, pain, neuropathy, fatigue, or sexual dysfunction, see [NCCN Guidelines for Survivorship](#).
- Bowel function changes: chronic diarrhea, incontinence, stool frequency, stool clustering, urgency, and/or cramping
 - ▶ Consider anti-diarrheal agents, bulk-forming agents, diet manipulation, pelvic floor rehabilitation, and protective undergarments.
 - ▶ Management of an ostomy
 - ◊ Consider participation in an ostomy support group or coordination of care with a health care provider specializing in ostomy care (ie, ostomy nurse).
 - ◊ Screen for distress around body changes ([NCCN Guidelines for Distress Management](#)) and precautions around involvement with physical activity ([SPA-A in the NCCN Guidelines for Survivorship](#)).

- Urogenital dysfunction after resection and/or pelvic radiation^{7,8}
 - ▶ Screen for sexual dysfunction, erectile dysfunction, dyspareunia, vaginal stenosis, and vaginal dryness.
 - ▶ Screen for urinary incontinence, frequency, and urgency.
 - ▶ Consider referral to urologist or gynecologist for persistent symptoms.
- Potential for pelvic fractures/decreased bone density after pelvic radiation
 - ▶ Consider bone density monitoring.

Counseling Regarding Healthy Lifestyle and Wellness⁹:

[NCCN Guidelines for Survivorship](#)

- Undergo all age- and gender-appropriate cancer and preventive health screenings as per national guidelines.
- Maintain a healthy body weight throughout life.
- Adopt a physically active lifestyle (at least 30 minutes of moderate-intensity activity on most days of the week). Activity recommendations may require modification based on treatment sequelae (ie, ostomy, neuropathy).
- Consume a healthy diet with an emphasis on plant sources. Diet recommendations may be modified based on severity of bowel dysfunction.
- Drink alcohol sparingly, if at all.
- Seek smoking cessation counseling as appropriate.

Additional health monitoring and immunizations should be performed as indicated under the care of a primary care physician. Survivors are encouraged to maintain a therapeutic relationship with a primary care physician throughout their lifetime.

[References on ANAL-D 2 of 2](#)

Note: All recommendations are category 2A unless otherwise indicated.



PRINCIPLES OF SURVIVORSHIP REFERENCES

- ¹ Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, D.C.:The National Academies Press; 2006.
- ² Schneider EC, Malin JL, Kahn KL, et al. Surviving colorectal cancer: patient-reported symptoms 4 years after diagnosis. *Cancer* 2007;110:2075-2082.
- ³ Sprangers MAG, Taal BG, Aaronson NK, te Velde A. Quality of life in colorectal cancer. Stoma vs. nonstoma patients. *Dis Colon Rectum* 1995;38:361-369.
- ⁴ Gami B, Harrington K, Blake P, et al. How patients manage gastrointestinal symptoms after pelvic radiotherapy. *Aliment Pharmacol Ther* 2003;18:987-994.
- ⁵ DeSnoo L, Faithfull S. A qualitative study of anterior resection syndrome: the experiences of cancer survivors who have undergone resection surgery. *Eur J Cancer Care (Engl)* 2006;15:244-251.
- ⁶ McGough C, Baldwin C, Frost C, Andreyev HJN. Role of nutritional intervention in patients treated with radiotherapy for pelvic malignancy. *Br J Cancer* 2004;90:2278-2287.
- ⁷ Lange MM, Marijnen CAM, Mass CP, et al. Risk factors for sexual dysfunction after rectal cancer treatment. *Eur J Cancer* 2009;45:1578-1588.
- ⁸ Lange MM, Mass CP, Marijnen CAM, et al. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. *Brit J Cancer* 2008;95:1020-1028.
- ⁹ Kushi LH, Byers T, Doyle C, et al; American Cancer Society 2006 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. *CA Cancer J Clin* 2006;56:254-281.

Note: All recommendations are category 2A unless otherwise indicated.



American Joint Committee on Cancer (AJCC) TNM Staging Classification for Anal Carcinoma (9th ed., 2022)

Table 1. Definitions for T, N, M

T Primary Tumor

- TX** Primary tumor not assessed
- T0** No evidence of primary tumor
- T1** Tumor less than or equal to 2 cm in greatest dimension
- T2** Tumor greater than 2 cm but less than or equal to 5 cm in greatest dimension
- T3** Tumor greater than 5 cm in greatest dimension
- T4** Tumor of any size invades adjacent organ(s), such as the vagina, urethra, or bladder

N Regional Lymph Nodes

- NX** Regional lymph nodes cannot be assessed
- N0** No tumor involvement of regional lymph node(s)
- N1** Tumor involvement of regional lymph node(s)
 - N1a** Tumor involvement of inguinal, mesorectal, superior rectal, internal iliac, or obturator lymph node(s)
 - N1b** Tumor involvement of external iliac lymph node(s)
 - N1c** Tumor involvement of N1b (external iliac) with any N1a node(s)

M Distant Metastasis

- cM0** No distant metastasis
- cM1** Distant metastasis
- pM1** Microscopic confirmation of distant metastasis

Table 2. AJCC Anatomic Stage/Prognostic Groups

	T	N	M
Stage I	T1	N0	M0
Stage IIA	T2	N0	M0
Stage IIB	T1-T2	N1	M0
Stage IIIA	T3	N0-N1	M0
Stage IIIB	T4	N0	M0
Stage IIIC	T4	N1	M0
Stage IV	Any T	Any N	M1

© 2022, American College of Surgeons, All Rights Reserved. *Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging System.*



ABBREVIATIONS

APR	abdominoperineal resection	TME	total mesorectal excision
AUC	area under the curve		
		3D-CRT	three-dimensional conformal radiation therapy
CTV	clinical target volume		
DRE	digital rectal examination		
FNA	fine-needle aspiration		
GBCA	gadolinium-based contrast agent		
GTV	gross tumor volume		
HIV	human immunodeficiency virus		
IGRT	image-guided radiation therapy		
IMRT	intensity-modulated radiation therapy		
OAR	organ(s) at risk		
PTV	planning target volume		
SBRT	stereotactic body radiation therapy		
SCC	squamous cell carcinoma		
SIB	simultaneous integrated boost		
SISCCA	superficially invasive squamous cell carcinoma		



NCCN Categories of Evidence and Consensus	
Category 1	Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
Category 2A	Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.
Category 2B	Based upon lower-level evidence, there is NCCN consensus (≥50%, but <85% support of the Panel) that the intervention is appropriate.
Category 3	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.

NCCN Categories of Preference	
Preferred intervention	Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.
Other recommended intervention	Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.
Useful in certain circumstances	Other interventions that may be used for selected patient populations (defined with recommendation).

All recommendations are considered appropriate.



NCCN Guidelines Version 4.2025

Anal Carcinoma

Discussion

This discussion corresponds to the NCCN Guidelines for Anal Carcinoma. Last updated May 30, 2025

SummaryMS-23

ReferencesMS-25

Table of Contents

OverviewMS-2

Guidelines Update Methodology.....MS-2

Literature Search Criteria.....MS-2

Sensitive/Inclusive Language Usage.....MS-2

Risk Factors.....MS-3

 Risk Reduction.....MS-4

Anatomy/HistologyMS-6

Pathology.....MS-7

Staging.....MS-7

Prognostic FactorsMS-8

Management of Anal CarcinomaMS-9

 Clinical Presentation/EvaluationMS-9

 Primary Treatment of Non-Metastatic Anal Carcinoma.....MS-10

 Surveillance Following Primary TreatmentMS-18

 Treatment of Locally Progressive or Recurrent Anal Carcinoma
 MS-19

 Treatment of Metastatic Anal Cancer.....MS-20

SurvivorshipMS-23



NCCN Guidelines Version 4.2025

Anal Carcinoma

Overview

An estimated 10,930 new cases (3560 male and 7370 female) of cancer involving the anus, anal canal, or anorectum will occur in the United States in 2025, accounting for approximately 3% of digestive system cancers.¹ 2030 deaths due to anal cancer are projected to occur in the United States in 2025.¹ Although considered to be a rare cancer, the incidence rate of invasive anal carcinoma in the United States increased by approximately 1.9-fold for males and 1.5-fold for females between the periods of 1973–1979 to 1994–2000 and has continued to increase since that time.^{2–4} According to an analysis of SEER data, the incidence of anal squamous carcinoma increased at a rate of 2.9% per year from 1992 to 2001.⁵ Supporting this, an analysis of the U.S. Cancer Statistics dataset reported an annual increase of 2.7% between 2001 to 2015 with the greatest increases in age groups ≥50 years,⁶ while the National Program of Cancer Registries and SEER programs showed similar trends from 2001 to 2016, with an annual percent change of 2.1% (95% CI, 1.7–2.5) overall, and 2.8% (95% CI, 2.5–3.1) in those ≥50 years of age.⁷ Increases in incidence of anal cancer during that time frame were especially noted for females ≥50 years of age. Anal cancer mortality rates (2001–2016) also rose, with an average increase of 3.1% per year.⁶

This Discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents the most common histologic form of the disease. Other groups have also published guidelines for the management of anal squamous cell carcinoma.^{8–10} Other types of cancers occurring in the anal region are addressed in other NCCN Guidelines; anal adenocarcinoma and anal melanoma are managed according to the NCCN Clinical Practice Guidelines (NCCN Guidelines) for Rectal Cancer (available at www.NCCN.org) and the NCCN Guidelines for Melanoma (available at www.nccn.org), respectively.

Guidelines Update Methodology

The complete details of the Development and Update of the NCCN Guidelines are available at www.NCCN.org.

Literature Search Criteria

Prior to the update of this version of the NCCN Clinical Practice Guidelines (NCCN Guidelines®) for Anal Carcinoma, an electronic search of the PubMed database was performed to obtain key literature in the field of anal cancer published since the previous Guidelines update, using the search terms: anal cancer or anal squamous cell carcinoma. The PubMed database was chosen because it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.¹¹

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Practice Guideline; Randomized Controlled Trials; Meta-Analysis; Systematic Reviews; and Validation Studies. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these Guidelines as discussed by the Panel during the Guidelines update have been included in this version of the Discussion section. Recommendations for which high-level evidence is lacking are based on the Panel's review of lower-level evidence and expert opinion.

Sensitive/Inclusive Language Usage

NCCN Guidelines strive to use language that advances the goals of equity, inclusion, and representation. NCCN Guidelines endeavor to use language that is person-first; not stigmatizing; anti-racist, anti-classist, anti-misogynist, anti-ageist, anti-ableist, and anti-weight-biased; and inclusive of individuals of all sexual orientations and gender identities. NCCN Guidelines incorporate non-gendered language, instead focusing



NCCN Guidelines Version 4.2025

Anal Carcinoma

on organ-specific recommendations. This language is both more accurate and more inclusive and can help fully address the needs of individuals of all sexual orientations and gender identities. NCCN Guidelines will continue to use the terms men, women, female, and male when citing statistics, recommendations, or data from organizations or sources that do not use inclusive terms. Most studies do not report how sex and gender data are collected and use these terms interchangeably or inconsistently. If sources do not differentiate gender from sex assigned at birth or organs present, the information is presumed to predominantly represent cisgender individuals. NCCN encourages researchers to collect more specific data in future studies and organizations to use more inclusive and accurate language in their future analyses.

Risk Factors

Anal carcinoma is associated with human papillomavirus (HPV) infection (anal-genital warts); a history of receptive anal intercourse or sexually transmitted disease; a history of cervical, vulvar, or vaginal cancer; immunosuppression after solid organ transplantation or human immunodeficiency virus (HIV) infection; hematologic malignancies; certain autoimmune disorders; and smoking.¹²⁻²⁰

The association between anal carcinoma and persistent infection with a high-risk form of HPV (eg, HPV-16; HPV-18) is especially strong.^{13,21,22} For example, a study of tumor specimens from more than 60 pathology laboratories in Denmark and Sweden showed that high-risk HPV DNA was detected in 84% of anal cancer specimens, with HPV-16 detected in 73%. In contrast, high-risk HPV was not detected in any of the rectal adenocarcinoma specimens analyzed.¹³ In addition, results of a systematic review of 35 peer-reviewed anal cancer studies that included HPV DNA testing results published up until July 2007 showed the prevalence of HPV-16/18 to be 72% in patients with invasive anal

cancer.²² Population and registry studies have found similar HPV prevalence rates in anal cancer specimens.^{23,24} A 2012 report from the U.S. Centers for Disease Control and Prevention (CDC) estimated that 86% to 97% of cancers of the anus are attributable to HPV infection.²⁵

Suppression of the immune system by the use of immunosuppressive drugs or HIV infection likely facilitates persistence of HPV infection of the anal region.^{26,27} Studies have shown that people with HIV (PWH) have an approximately 15- to 35-fold increased likelihood of being diagnosed with anal cancer compared with the general population.²⁸⁻³¹ In PWH, the standardized incidence rate of anal carcinoma per 100,000 person-years in the United States, estimated to be 19.0 in 1992 through 1995, increased to 78.2 during 2000 through 2003.²⁷ This result likely reflects both the survival benefits of modern antiretroviral therapy (ART) and the lack of an impact of ART on the progression of anal cancer precursors. The incidence rate of anal cancer has been reported to be 131 per 100,000 person-years in males who have sex with males (MSM) with HIV in North America, and in 3.9 to 30 per 100,000 person years in females living with HIV.^{32,33} An analysis of the French Hospital Database on HIV showed a highly elevated risk of anal cancer in PWH, including in those who were on therapy and whose CD4+ T-cell counts were high.³⁴ The data also revealed an increasing incidence of anal cancer in the PWH population over time. However, some evidence suggests that prolonged ART (>24 months) may be associated with a decrease in the incidence of high-grade anal intraepithelial neoplasia (AIN).³⁵

A meta-analysis of anal cancer incidence across risk groups found that the incidence of anal cancer in solid organ transplant recipients increased both by age and years since transplant.²⁰ Incidence rates rose from 0.0 and 3.1 per 100,000 person years in males and females >30 years to 13.4 and 25.9 per 100,000 person years in males and



NCCN Guidelines Version 4.2025

Anal Carcinoma

females ≥ 60 years. Years since transplant appeared to identify an even higher risk than age, with an incidence rate of 24.5 and 29.6 per 100,000 person years in males and females ≥ 10 years post-transplant, respectively. This study also assessed risk in individuals with autoimmune diseases and found incidence rates of 10, 6, and 3 per 100,000 person years for patients with systemic lupus erythematosus, ulcerative colitis, and Crohn's disease, respectively.

A retrospective study used data from 13 population-based HIV and cancer registries in the United States from 2001 to 2019, to identify predictors of survival between individuals with anal cancer with and without HIV. Overall, HIV was associated with anal cancer-specific higher mortality, especially in female compared to male individuals (2.47 vs. 1.35 times more likely, respectively). Results from this study highlight the importance of early HIV screening in female individuals with anal cancer for risk reduction.³⁶

Risk Reduction

The Lower Anogenital Squamous Terminology (LAST) Project has recommended unified terminology across lower anogenital sites. As such, condyloma and AIN 1 are referred to as low-grade squamous intraepithelial lesions (LSIL) and AIN 2 and 3 as high-grade squamous intraepithelial lesions (HSIL).³⁷ HSIL (AIN 2/3) can be a precursor to anal cancer.³⁸⁻⁴¹ LSIL and HSIL are diagnosed by digital anorectal examination (DRE/DARE) and high-resolution anoscopy (HRA), followed by anal pap smear (cytology) and/or biopsy.^{42,43} A prospective cohort study of 550 MSM who were HIV-positive found the rate of conversion of HSIL to anal cancer to be 18% (7/38) at a median follow-up of 2.3 years.⁴¹ A large randomized controlled trial known as the ANCHOR Study compared topical or ablative treatment with monitoring every 6 months with HRA in 4459 PWH with anal HSIL.⁴⁴ With a median follow-up of 25.8 months, 9 cases of anal cancer were diagnosed in the

treatment group compared to 21 cases in the active monitoring group. The rate of progression to anal cancer was 57% lower with treatment compared to active monitoring (95% CI, 6–80; $P = .03$). Progression from anal HSIL to cancer was 402/100,000 person-years among individuals whose HSIL was monitored without treatment, with a cumulative progression to cancer of 1.8% over 4 years. Given the relatively young median age of the participants of 51 years and an expected normal life expectancy, this progression rate could lead to a substantial cumulative risk of developing anal cancer in the absence of HSIL treatment.

The optimal approach to screening remains an area of uncertainty, but the benefits of current screening recommendations for anal HSIL are potentially quite large.⁴⁵⁻⁵¹ Systematic reviews and meta-analyses have suggested that anal cytology is effective in detection of LSIL/HSIL, particularly for individuals at high-risk.⁵²⁻⁵⁴ Based on these studies and recent results from the ANCHOR Study, entities have published guidelines containing general recommendations for anal cancer screening.⁵⁵ The International Anal Neoplasia Society (IANS) and the CDC's *Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV* recommend initial screening that includes cytology, and HPV screening via either hrHPV or hrHPV-cytology co-testing, DARE, and anoscopy (HRA, if available).^{56,57} According to IANS, if there are no abnormalities observed, repeating screening in 12 months is recommended, but if abnormalities are present (such as LSIL/HSIL) HRA is preferred.⁵⁶ The CDC guidelines concur with the IANS' follow-up recommendations post-results, but suggest initiating screening with HRA, if available, due to its higher sensitivity to abnormalities.⁵⁷

Early screening for anal cancer is essential for high-risk groups, but the screening age for these individuals remains undetermined. Recently,



NCCN Guidelines Version 4.2025

Anal Carcinoma

the IANS published consensus guidelines for anal cancer screening, including different risk groups and appropriate age to initiate screening.⁵⁶ They define two risk categories that are differentiated due to their incidence compared to the general population. The Risk Category A (incidence of ≥ 10 -fold higher) includes PWH, MSM and transgender women without HIV, individuals with a history of vulvar HSIL or cancer, and solid organ transplant recipients. The recommended age to start screening MSM with HIV and transgender women with HIV is 35 years. For women with HIV, MSW with HIV, MSM without HIV, and transgender women without HIV, the recommended screening age is 45 years. The recommended screening time for individuals with previous vulvar HSIL or cancer is within 1 year of diagnosis and 10 years post-transplant for transplant recipients. Risk Category B (incidence of up to 10-fold higher) includes individuals with previous cervical/vaginal HSIL or cancer, patients who present with perianal warts or have persistent cervical infection with HPV-16 (defined as over 1 year), and immunocompromised individuals. The recommended age to get anal cancer screening for Risk Category B should be decided between the patient and healthcare provider, but IANS suggests age 45 years. For more information on these risk categories and screening ages, refer to the [International Anal Neoplasia Society's consensus guidelines for anal cancer screening](#).

Prior to the publication of ANCHOR, guidelines for the treatment of LSIL/HSIL (AIN 1, 2, and 3) have been developed by several groups, including the American Society of Colon and Rectal Surgeons (ASCRS).^{50,58-60} Treatment recommendations vary widely because high-level evidence in the field was limited prior to ANCHOR.⁵⁸ Most participants in the ANCHOR Study were treated with office-based, targeted electrocautery, indicating that this approach could be considered as a first line of therapy.⁴⁴ An earlier randomized controlled trial in 246 MSM with HIV found that electrocautery was superior to both

topical imiquimod and topical fluorouracil in the treatment of AIN overall.⁶¹ The subgroup with perianal AIN, as opposed to intra-anal AIN, appeared to respond better to imiquimod. Regardless of treatment, recurrence rates were high, and careful follow-up is likely needed.

HPV Immunization

A quadrivalent HPV vaccine is available and has been shown to be effective in preventing persistent cervical infection with HPV-6, -11, -16, or -18 as well as in preventing high-grade cervical intraepithelial neoplasia related to these strains of the virus.⁶²⁻⁶⁴ The vaccine has also been shown to be efficacious in young males at preventing genital lesions associated with HPV-6, -11, -16, or -18 infection.⁶⁵ A substudy of a larger double-blind study assessed the efficacy of the vaccine for the prevention of AIN and anal cancer related to infection with HPV-6, -11, -16, or -18 in MSM.⁶⁶ In this study, 602 healthy MSM aged 16 to 26 years were randomized to receive the vaccine or a placebo. While none of the participants in either arm developed anal cancer during the 3-year follow-up period, there were 5 cases of HSIL (grade 2/3 AIN) associated with one of the vaccine strains in the vaccine arm and 24 such cases in the placebo arm in the per-protocol population, giving an observed efficacy of 77.5% (95% CI, 39.6–93.3). Since high-grade AIN is known to have the ability to progress to anal cancer,³⁸⁻⁴⁰ these results suggest that use of the quadrivalent HPV vaccine in MSM may reduce the risk of anal cancer in this population.

A bivalent HPV vaccine against HPV-16 and -18 is also available.⁶⁷ In a randomized, double-blind controlled trial of female patients in Costa Rica, the vaccine was 83.6% effective against initial anal HPV-16/18 infection (95% CI, 66.7–92.8).^{68,69} It has also been shown to be effective at preventing high-grade cervical intraepithelial neoplasias in young people.⁷⁰ The effect on precancerous anal lesions has not yet been reported.



NCCN Guidelines Version 4.2025

Anal Carcinoma

A 9-valent HPV vaccine is also now available, protecting against HPV-6, -11, -16, -18, -31, -33, -45, -52, and -58.⁷¹ Targeting the additional strains over the quadrivalent vaccine is predicted to prevent an additional 464 cases of anal cancer annually.⁷² This vaccine was compared to the quadrivalent vaccine in an international, randomized phase IIb–III study that included more than 14,000 female patients.⁷³ The 9-valent vaccine was noninferior to the quadrivalent vaccine for antibody response to HPV-6, -11, -16, and -18 and prevented infection and disease related to the other viral strains included in the vaccine. The calculated efficacy of the 9-valent vaccine was 96.7% (95% CI, 80.9–99.8) for the prevention of high-grade cervical, vulvar, or vaginal disease related to those strains. A follow-up study of a phase III trial showed that the 9-valent vaccine sustained efficacy and immunogenicity, and aided in prevention of HPV incidence after 10 years post-vaccination.⁷⁴

The Advisory Committee on Immunization Practices (ACIP) recommends routine use of the 9-valent vaccine in children aged 11 and 12 years, as well as catch-up vaccination for individuals through 26 years of age who have not been previously vaccinated.^{75–78} The American Academy of Pediatrics concurs with this vaccination schedule.⁷⁹ ASCO released a statement regarding HPV vaccination for cancer prevention with the goal of increasing vaccine uptake.⁸⁰ In 2018, the U.S. Food and Drug Administration (FDA) expanded use of the 9-valent vaccine to include individuals aged 27 through 45 years,⁸¹ and the ACIP voted in 2019 to recommend vaccination, based on shared clinical decision-making, for individuals in this age range who are not adequately vaccinated.

Anatomy/Histology

The anal region is comprised of the anal canal and the perianal region, dividing anal cancers into two primary locations. The anal canal is the

most proximal portion of the anal region extending distally into the perianal region. The 9th Edition of the AJCC Cancer Staging Manual defines anal canal cancers as tumors that cannot be entirely seen when the buttocks are gently pressed.⁸² The corresponding definitions for perianal cancer are tumors that 1) arise within the skin distal to or at the squamous mucocutaneous junction; 2) can be visualized completely when the buttocks are gently pressed; and 3) are within 5 cm of the anus.⁸² Various definitions of the anal canal exist such as functional, surgical, anatomic and histologic that are based on particular physical/anatomic landmarks or microscopic features.

Histologically, the anal canal can be divided into thirds. The most proximal or upper zone is lined by glandular columnar epithelium with goblet cells, similar to colorectal mucosa. The middle zone is characterized by transitional epithelium, which demonstrates a range of morphologies including scattered goblet cells intermixed with squamous and urothelial features. The distal lower third is comprised of nonkeratinizing squamous epithelium devoid of epidermal appendages (hair follicles, apocrine glands and sweat glands). Moving distally into the perianal region, squamous mucosa merges with keratinized perianal skin at the anal margin (anal verge).^{15,82–84}

The anatomic anal canal begins at the anorectal ring and extends to the anal verge (ie, squamous mucocutaneous junction with the perianal skin).⁸⁵

Functionally, the anal canal is defined by the sphincter muscles. The superior border of the functional anal canal, separating it from the rectum, has been defined as the palpable upper border of the anal sphincter and puborectalis muscles of the anorectal ring. It is approximately 3 to 5 cm in length, and its inferior border starts at the anal verge, the lowermost edge of the sphincter muscles, corresponding to the introitus of the anal orifice.^{15,83,86} The functional definition of the



NCCN Guidelines Version 4.2025

Anal Carcinoma

anal canal is primarily used in the radical surgical treatment of anal cancer and is used in these guidelines to differentiate between treatment options. The anal margin starts at the anal verge and includes the perianal skin over a 5- to 6-cm radius from the squamous mucocutaneous junction.⁸³ Tumors can involve the anal canal, the anal margin, and the perianal skin.

Pathology

Most primary cancers of the anal canal are of squamous cell histology.⁸³ Earlier editions of the WHO classification of tumors of the anal canal designated squamous cell carcinoma (SCC) of the anal canal as cloacogenic and identified subtypes as large-cell keratinizing, large-cell non-keratinizing (transitional), or basaloid.⁸⁷ In the most current 5th edition, different histologic patterns are described. However, all subtypes are included under a single diagnosis of SCC.^{15,82,88,89} Reasons for this change include the following: both cloacogenic (which is sometimes used interchangeably with the term basaloid) and transitional tumors are now considered to be non-keratinizing tumors; it has been reported that both keratinizing and non-keratinizing tumors have a similar natural history and prognosis⁸⁸; and a mixture of cell types is frequently present in these tumors.^{83,88,90} No distinction between squamous anal canal tumors based on cell type has been made in these guidelines. Although the existence of one low-grade subtype, verrucous carcinoma (VC), is worth mentioning as rendering a definitive diagnosis on superficial biopsy material is challenging. This lesion demonstrates marked exophytic and endophytic growth without features of HPV cytopathic effect or high-grade cytologic atypia. When conventional SCC is identified arising in VC the diagnosis should be SCC as these lesions have similar biology as conventional SCC. Other less common anal canal tumors, not addressed in these guidelines, include adenocarcinomas in the rectal mucosa or the anal glands, small cell (anaplastic) carcinoma, undifferentiated cancers, and melanomas.⁸³

Perianal squamous cell carcinomas are more likely than those of the anal canal to be well-differentiated and keratinizing large-cell types,⁹¹ but they are not characterized in the guidelines according to cell type. The presence of skin appendages (eg, hair follicles, sweat glands) in perianal tumors can distinguish them from anal canal tumors. However, it is not always possible to distinguish between anal canal and perianal squamous cell carcinoma since tumors can involve both areas.

Lymph drainage of anal cancer tumors is dependent on the location of the tumor in the anal region: cancers in the perianal skin and the region of the anal canal distal to the dentate line drain mainly to the superficial inguinal nodes.^{82,83} Lymph drainage at and proximal to the dentate line is directed toward the anorectal, perirectal, and paravertebral nodes and to some of the nodes of the internal iliac system. More proximal cancers drain to perirectal nodes and to nodes of the inferior mesenteric system. Therefore, distal anal cancers present with a higher incidence of inguinal node metastases. Because the lymphatic drainage systems throughout the anal canal are not isolated from each other, however, inguinal node metastases can occur in proximal anal cancer as well.⁸³

The College of American Pathologists publishes protocols for the pathologic examination and reporting of anal tumors following excision or transabdominal resection. The most recent updates incorporating AJCC 9th edition updates were made in September 2023 and June 2022, respectively.^{92,93}

Staging

The TNM staging system for anal canal cancer developed by the AJCC is detailed in the guidelines.⁸² Because current recommendations for the primary treatment of anal canal cancer do not involve a surgical excision, most tumors are staged clinically with an emphasis on the size of the primary tumor as determined by direct examination and



NCCN Guidelines Version 4.2025

Anal Carcinoma

microscopic confirmation. A tumor biopsy is required. Rectal ultrasound to determine depth of tumor invasion is not used in the staging of anal cancer (see *Clinical Presentation/Evaluation*, below).

In the past, these guidelines have used the AJCC TNM skin cancer system for the staging of perianal cancer since the two types of cancers have a similar biology. However, the 7th edition of the AJCC Cancer Staging Manual included substantial changes to the cutaneous squamous cell carcinoma stagings,⁹⁴ making them much less appropriate for the staging of perianal cancers. Furthermore, many perianal cancers have involvement of the anal canal or have high-grade, pre-cancerous lesions in the anal canal. It is important to look for such anal canal involvement, particularly if conservative management (simple excision) is being contemplated. Many patients, particularly PWH, could be significantly undertreated. For these reasons, these guidelines use the AJCC anus staging system for both anal canal and perianal tumors.

The prognosis of anal carcinoma is related to the size of the primary tumor and the presence of lymph node metastases.¹⁵ According to the SEER database,⁹⁵ between 1999 and 2006, 50% of anal carcinomas were localized at initial diagnosis; these patients had an 80% 5-year survival rate. Approximately 29% of patients had anal carcinoma that had already spread to regional lymph nodes at diagnosis; these patients had a 60% 5-year survival rate. The 12% of patients presenting with distant metastasis demonstrated a 30.5% 5-year survival rate.⁹⁵ In a retrospective study of 270 patients treated for anal canal cancer with radiation therapy (RT) between 1980 and 1996, synchronous inguinal node metastasis was observed in 6.4% of patients with tumors staged as T1 or T2, and in 16% of patients with T3 or T4 tumors.⁹⁶ In patients with N2–3 disease, survival was related to T-stage rather than nodal involvement with respective 5-year survival rates of 72.7% and 39.9%

for patients with T1–T2 and T3–T4 tumors; however, the number of patients involved in this analysis was small.⁹⁶ An analysis of more than 600 patients with non-metastatic anal carcinoma from the RTOG 98-11 trial also found that the tumor and node categories impacted clinical outcomes such as overall survival (OS), disease-free survival (DFS), and colostomy failure, with the worst prognoses for patients with T4,N0 and T3–4,N+ disease.⁹⁷

By the 8th edition of AJCC Cancer Staging Manual, the former N2 and N3 categories by locations of positive nodes were removed.⁹⁸ New categories of N1a, N1b, and N1c were defined and then further refined in the 9th edition.⁸² N1a now represents metastasis in inguinal, mesorectal, superior rectal, internal iliac, or obturator nodes. N1b represents metastasis in external iliac nodes. N1c represents metastasis in external iliac with any N1a nodes. However, initial therapy of anal cancer does not typically involve surgery, and the true lymph node status may not be determined accurately by clinical and radiologic evaluation. Fine-needle aspiration (FNA) biopsy of inguinal nodes can be considered if tumor metastasis to these nodes is suspected. In a series of patients with anal cancer who underwent an abdominoperineal resection (APR), it was noted that pelvic nodal metastases were often <0.5 cm,⁹⁹ suggesting that routine radiologic evaluation with CT and FDG-PET/CT scan may not be reliable in the determination of lymph node involvement (discussed in more detail in *Clinical Presentation/Evaluation*, below).

Prognostic Factors

Multivariate analysis of data from the RTOG 98-11 trial showed that male sex and positive lymph nodes were independent prognostic factors for DFS in patients with anal cancer treated with 5-FU and radiation and either mitomycin or cisplatin.¹⁰⁰ Male sex, positive nodes, and tumor size >5 cm were independently prognostic for worse OS. A



NCCN Guidelines Version 4.2025

Anal Carcinoma

secondary analysis of this trial found that tumor diameter could also be prognostic for colostomy rate and time to colostomy.¹⁰¹ These results are consistent with earlier analyses from the EORTC 22861 trial, which found male sex, lymph node involvement, and skin ulceration to be prognostic for worse survival and local control.¹⁰² Similarly, multivariate analyses of data from the ACT I trial also showed that positive lymph nodes and male sex are prognostic indicators for higher local regional failure, anal cancer death, and lower OS.¹⁰³

Data suggest that HPV- and/or p16-positivity are prognostic for improved OS in patients with anal carcinoma.¹⁰⁴⁻¹⁰⁷ In a retrospective study of 143 tumor samples, p16-positivity was an independent prognostic factor for OS (hazard ratio [HR], 0.07; 95% CI, 0.01–0.61; $P = .016$).¹⁰⁵ Another study of 95 patients found similar results.¹⁰⁴

Management of Anal Carcinoma

Clinical Presentation/Evaluation

Approximately 45% of patients with anal carcinoma present with rectal bleeding, while approximately 30% have either pain or the sensation of a rectal mass.¹⁵ Following confirmation of squamous cell carcinoma by biopsy, the recommendations of the NCCN Anal Carcinoma Guidelines Panel for the clinical evaluation of patients with anal canal or perianal cancer are very similar.

The Panel recommends a thorough examination/evaluation, including a careful DRE, an anoscopic examination, and palpation of the inguinal lymph nodes, with FNA and/or excisional biopsy of nodes found to be enlarged by either clinical or radiologic examination. Evaluation of pelvic lymph nodes with CT or MRI of the pelvis is also recommended. These methods can also provide information on whether the tumor involves other abdominal/pelvic organs; however, assessment of T stage is primarily performed through clinical examination. A CT scan of the

abdomen is also recommended to assess possible disease dissemination. Since veins of the anal region are part of the venous network associated with systemic circulation,⁸³ chest CT scan is performed to evaluate for pulmonary metastasis. Gynecologic exam, including cervical cancer screening, is suggested due to the association of anal cancer and HPV.¹³ A discussion of infertility risks and counseling on fertility preservation, if appropriate, should be carried out prior to the start of treatment.

HIV testing should be performed if the patient's HIV status is unknown, because the risk of anal carcinoma has been reported to be higher in PWH.¹⁷ Furthermore, about 13% of people in the United States who are infected with HIV are not aware of their infection status,¹⁰⁸ and individuals who are unaware of their HIV-positive status do not receive the clinical care they need to reduce HIV-related morbidity and mortality and may unknowingly transmit HIV.¹⁰⁹ HIV testing may be particularly important in people with cancer, because identification of HIV infection has the potential to improve clinical outcomes.¹¹⁰ The CDC recommends HIV screening for all individuals in all health care settings unless the patient declines testing (opt-out screening).¹¹¹

FDG-PET/CT scanning, or FDG-PET/MRI, can be considered to verify staging before treatment. FDG-PET/CT scanning has been reported to be useful in the evaluation of pelvic nodes, even in patients with anal canal cancer who have normal-sized lymph nodes on CT imaging.¹¹²⁻¹¹⁷ A systematic review and meta-analysis of seven retrospective and five prospective studies calculated pooled estimates of sensitivity and specificity for detection of lymph node involvement by FDG-PET/CT to be 56% (95% CI, 45–67) and 90% (95% CI, 86–93), respectively.¹¹³ A more recent meta-analysis of 17 clinical studies calculated the pooled sensitivity and specificity for detection of lymph node involvement by FDG-PET/CT at 93% and 76%, respectively.¹¹⁸ The use of FDG-PET or



NCCN Guidelines Version 4.2025

Anal Carcinoma

FDG-PET/CT led to upstaging in 5% to 38% of patients and downstaging in 8% to 27% of patients. Another systematic review and meta-analysis found FDG-PET/CT to change nodal status and TNM stage in 21% and 41% of patients, respectively.¹¹⁹ FDG-PET/CT results can also impact radiation therapy planning, as systematic reviews and meta-analyses have shown that treatment plan modifications occurred in 12% to 59% of patients based on FDG-PET/CT results.^{118,120} The Panel does not consider FDG-PET/CT to be a replacement for a diagnostic CT.

According to a systematic review and meta-regression, the proportion of individuals who are node-positive by pretreatment clinical imaging has increased from 15.3% (95% CI, 10.5–20.1) in 1980 to 37.1% (95% CI, 34.0–41.3) in 2012 ($P < .0001$), likely resulting from the increased use of more sensitive imaging techniques.¹²¹ This increase in lymph node positivity was associated with improvements in OS for both the lymph-node-positive and the lymph-node-negative groups. Because the proportion of patients with T3/T4 disease remained constant and therefore disease is not truly being diagnosed at more advanced stages over time, the authors attribute the improved OS results to the Will Rogers effect: The average survival of both groups increases as patients with worse-than-average survival in the node-negative group migrate to the node-positive group, in which their survival is better than average. Thus, the survival of individuals has not necessarily improved over time, even though the average survival of each group has. Using simulated scenarios, the authors further conclude that the actual rate of true node-positivity is likely $<30\%$, suggesting that it is possible some patients are being misclassified and overtreated with the increased use of highly sensitive imaging.

Primary Treatment of Non-Metastatic Anal Carcinoma

In the past, patients with invasive anal carcinoma were routinely treated with an APR; however, local recurrence rates were high, 5-year survival was only 40% to 70%, and the morbidity with a permanent colostomy was considerable.¹⁵ In 1974, Nigro and coworkers observed complete tumor regression in some patients with anal carcinoma treated with preoperative 5-FU-based concurrent chemotherapy and radiation (chemoRT) including either mitomycin or porfiromycin, suggesting that it might be possible to cure anal carcinoma without surgery and permanent colostomy.¹²² Subsequent nonrandomized studies using similar regimens and varied doses of chemoRT provided support for this conclusion.^{123,124} Results of randomized trials evaluating the efficacy and safety of administering chemotherapy with RT support the use of combined modality therapy in the treatment of anal cancer.¹⁸ Summaries of clinical trials involving patients with anal cancer have been presented,^{125,126} and several key trials are discussed below.

Chemotherapy

A phase III study from the EORTC compared the use of chemoRT (5-FU plus mitomycin) to RT alone in the treatment of anal carcinoma. Results from this trial showed that patients in the chemoRT arm had an 18% higher rate of locoregional control at 5 years and a 32% longer colostomy-free interval.¹⁰² The United Kingdom Coordinating Committee on Cancer Research (UKCCCR) randomized ACT I trial confirmed that chemoRT with 5-FU and mitomycin was more effective in controlling local disease than RT alone (relative risk [RR], 0.54; 95% CI, 0.42–0.69; $P < .0001$), although no significant differences in OS were observed at 3 years.¹²⁷ A published follow-up study on these patients demonstrates that a clear benefit of chemoRT remains after 13 years, including a benefit in OS.¹²⁸ The median survival was 5.4 years in the RT arm and 7.6 years in the chemoRT arm. There was also a reduction in the risk of dying from anal cancer (HR, 0.67; 95% CI, 0.51–0.88; $P = .004$). A



NCCN Guidelines Version 4.2025

Anal Carcinoma

systematic review and meta-analysis comparing outcomes in individuals with stage I anal carcinoma found an increased 5-year OS in patients treated with chemoRT compared to RT alone (RR, 1.18; 95% CI, 1.10–1.26; $P < .00001$) but no significant difference in 5-year DFS (RR, 1.01; 95% CI, 0.92–1.11; $P = 0.87$).¹²⁹ Conversely, a population-based cohort analysis of Medicare-eligible (>65 years of age or with an eligible disability) patients with stage I anal cancer showed no difference in OS, cause-specific survival, colostomy-free survival, or DFS with chemoRT versus RT alone after adjustment using propensity score methods.¹³⁰ Therefore, this study concludes that radiation alone may allow for adequate oncologic outcomes for highly selected patients with stage I anal cancer, although it is important to note that this study did not differentiate between anal canal and perianal cancers. Current NCCN Guideline *Recommendations for the Primary Treatment of Anal Canal Cancer* and *Recommendations for the Primary Treatment of Perianal Cancer* can be found below.

A few studies have addressed the efficacy and safety of specific chemotherapeutic agents in the chemoRT regimens used in the treatment of anal carcinoma.^{100,131,132} In a phase III Intergroup study, patients receiving chemoRT with the combination of 5-FU and mitomycin had a lower colostomy rate (9% vs. 22%; $P = .002$) and a higher 4-year DFS (73% vs. 51%; $P = .0003$) compared with patients receiving chemoRT with 5-FU alone, indicating that mitomycin is an important component of chemoRT in the treatment of anal carcinoma.¹³² The OS rate at 4 years was the same for the two groups, however, reflecting the ability to treat recurrent patients with additional chemoRT or an APR. The phase II JROSG 10-2 trial of 31 individuals with squamous cell anal cancer treated with concurrent chemoRT with 5-FU and mitomycin in Japan has reported 2-year DFS, OS, local control, and colostomy-free survival of 77.4%, 93.5%, 83.9%, and 80.6%, respectively.¹³³

Capecitabine, an oral fluoropyrimidine prodrug, is an accepted alternative to 5-FU in the treatment of colon and rectal cancer.¹³⁴⁻¹³⁷ Capecitabine has been assessed as an alternative to 5-FU in chemoRT regimens for non-metastatic anal cancer.¹³⁸⁻¹⁴¹ Doses throughout the radiation course on treatment days may offer improved radiation sensitization compared to two courses of 5-FU infusion during the chemoRT course. A retrospective study compared 58 patients treated with capecitabine to 47 patients treated with infusional 5-FU; both groups also received mitomycin and concurrent radiation.¹⁴⁰ No significant differences were seen in clinical complete response, 3-year locoregional control, 3-year OS, or colostomy-free survival between the two groups of patients. Another retrospective study compared 27 patients treated with capecitabine to 62 patients treated with infusional 5-FU; as in the other study, both groups also received mitomycin and radiation.¹³⁹ Grade 3/4 hematologic toxicities were significantly lower in the capecitabine group, with no oncologic outcomes reported. A phase II study found that chemoRT with capecitabine and mitomycin was safe and resulted in a 6-month locoregional control rate of 86% (95% CI, 0.72–0.94) in individuals with localized anal cancer.¹⁴² Although data for this regimen are limited, the Panel recommends mitomycin/capecitabine plus radiation as an alternative to mitomycin/5-FU plus radiation in the setting of stage I through III anal cancer.

Cisplatin as a substitute for 5-FU was evaluated in a phase II trial, and results suggest that cisplatin-containing and 5-FU-containing chemoRT may be comparable for treatment of locally advanced anal cancer.¹³¹

The efficacy of replacing mitomycin with cisplatin has also been assessed. The phase III UK ACT II trial compared cisplatin with mitomycin and also looked at the effect of additional maintenance chemotherapy following chemoRT.¹⁴³ In this study, more than 900 individuals with newly diagnosed anal cancer were randomly assigned



NCCN Guidelines Version 4.2025

Anal Carcinoma

to primary treatment with either 5-FU/mitomycin or 5-FU/cisplatin with radiotherapy. A continuous course (ie, no treatment gap) of radiation of 50.4 Gy was administered in both arms, and patients in each arm were further randomized to receive two cycles of maintenance therapy with 5-FU and cisplatin or no maintenance therapy. At a median follow-up of 5.1 years, no differences were observed in the primary endpoint of complete response rate in either arm for the chemoRT comparison or in the primary endpoint of progression-free survival (PFS) for the comparison of maintenance therapy versus no maintenance therapy. In addition, a secondary endpoint, colostomy, showed no differences based on the chemotherapeutic components of chemoRT. These results demonstrate that replacement of mitomycin with cisplatin in chemoRT does not affect the rate of complete response, nor does administration of maintenance therapy decrease the rate of disease recurrence following primary treatment with chemoRT in patients with anal cancer.

Cisplatin as a substitute for mitomycin in the treatment of patients with non-metastatic anal carcinoma was also evaluated in the randomized phase III Intergroup RTOG 98-11 trial. The role of induction chemotherapy was also assessed. In this study, 682 patients were randomly assigned to receive either: 1) induction 5-FU plus cisplatin for two cycles followed by concurrent chemoRT with 5-FU and cisplatin; or 2) concurrent chemoRT with 5-FU and mitomycin.^{100,144} A significant difference was observed in the primary endpoint, 5-year DFS, in favor of the mitomycin group (57.8% vs. 67.8%; $P = .006$).¹⁴⁴ Five-year OS was also significantly better in the mitomycin arm (70.7% vs. 78.3%; $P = .026$).¹⁴⁴ In addition, 5-year colostomy-free survival showed a trend towards statistical significance (65.0% vs. 71.9%; $P = .05$), again in favor of the mitomycin group. Since the two treatment arms in the RTOG 98-11 trial differed with respect to use of either cisplatin or mitomycin in concurrent chemoRT as well as inclusion of induction

chemotherapy in the cisplatin-containing arm, it is difficult to attribute the differences to the substitution of cisplatin for mitomycin or to the use of induction chemotherapy.^{125,145} However, since ACT II demonstrated that the two chemoRT regimens are equivalent, some have suggested that results from RTOG 98-11 suggest that induction chemotherapy is probably detrimental.¹⁴⁶

Results from ACCORD 03 also suggest that there is no benefit of a course of chemotherapy given prior to chemoRT.¹⁴⁷ In this study, individuals with locally advanced anal cancer were randomized to receive induction therapy with 5-FU/cisplatin or no induction therapy followed by chemoRT (they were further randomized to receive an additional radiation boost or not). No differences were seen between tumor complete response, tumor partial response, 3-year colostomy-free survival, local control, event-free survival, or 3-year OS. After a median follow-up of 50 months, no advantage to induction chemotherapy (or to the additional radiation boost) was observed, consistent with earlier results. A systematic review of randomized trials also showed no benefit to a course of induction chemotherapy.¹⁴⁸

A retrospective analysis, however, suggests that induction chemotherapy preceding chemoRT may be beneficial for the subset of patients with T4 anal cancer.¹⁴⁹ The 5-year colostomy-free survival rate was significantly better in T4 patients who received induction 5-FU/cisplatin compared to those who did not (100% vs. $38 \pm 16.4\%$; $P = .0006$).

The combination of 5-FU, mitomycin C, and cisplatin has also been studied in a phase II trial, but was found to be too toxic.¹⁵⁰ The safety and efficacy of capecitabine/oxaliplatin with radiation for the treatment of localized anal cancer has been investigated in a phase II study, which reported that the regimen was safe, with promising efficacy, although larger trials would be needed to confirm these results.¹⁵¹



NCCN Guidelines Version 4.2025

Anal Carcinoma

There has also been interest in the use of biologic therapies for the treatment of anal cancer. A phase 3 trial is investigating the use of the programmed cell death protein 1 (PD-1) inhibitor, nivolumab, following combined modality therapy for high-risk anal carcinoma.¹⁵² This trial has completed enrollment of 344 participants and results are pending. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor, whose anti-tumor activity is dependent on the presence of wild-type *KRAS*.¹⁵³ Because *KRAS* mutations appear to be very rare in anal cancer,^{154,155} the use of an EGFR inhibitor such as cetuximab has been considered to be a promising avenue of investigation. The phase II ECOG 3205 and AIDS Malignancy Consortium 045 trials evaluated the safety and efficacy of cetuximab with cisplatin/5-FU and radiation in immunocompetent (E3205) and PWH (AMC045) with anal squamous cell carcinoma.^{156,157} Results from E3205 and AMC045 were published in 2017. In a post hoc analysis of E3205, the 3-year locoregional failure rate was 21% (95% CI, 7–26) by Kaplan-Meier estimate.¹⁵⁶ The toxicities associated with the regimen were substantial, with grade 4 toxicity occurring in 32% of the study population and three treatment-associated deaths (5%). In AMC045, the 3-year locoregional failure rate was 20% (95% CI, 10–37) by Kaplan-Meier estimate.¹⁵⁷ Grade 4 toxicity and treatment-associated rates were similar to that seen in E3205, at 26% and 4%, respectively. Two other trials that have assessed the use of cetuximab in this setting have also found it to increase toxicity, including a phase I study of cetuximab with 5-fluorouracil, cisplatin, and radiation.¹⁵⁸ The ACCORD 16 phase II trial, which was designed to assess response rate after chemoRT with cisplatin/5-FU and cetuximab, was terminated prematurely because of extremely high rates of serious adverse events.¹⁵⁹ The 15 evaluable patients from ACCORD 16 had a 4-year DFS rate of 53% (95% CI, 28–79), and two of the five patients who completed the planned treatments had locoregional recurrences.¹⁶⁰

For older patients or those who are unlikely to tolerate mitomycin, the optimal chemotherapy regimen remains uncertain. Some NCCN Panel members have used a combination of weekly cisplatin and daily 5-FU on days of radiation¹⁶¹ for chemoRT in localized anal cancer. Other potential strategies for this patient population may include capecitabine plus RT or RT alone (without chemotherapy). However, due to a lack of data supporting this approach and differing strategies among Panel members, recommendations have not yet been defined for individuals with anal cancer who are not candidates for intensive therapy. Use of a geriatric assessment to guide management and elicitation of the patient's goals and objectives with regard to their cancer diagnosis is critical to inform shared decision-making discussions in these situations (See the NCCN Guidelines for Older Adult Oncology, available at www.NCCN.org).

Radiation Therapy

Prior to the start of RT, patients should be counseled on infertility risks and given information regarding sperm banking or oocyte, egg, or ovarian tissue banking, as appropriate. In addition, patients should be counseled on risks for early treatment-induced menopause and changes to sexual function. See the NCCN Guidelines for Survivorship (available at www.NCCN.org) and the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology (available at www.NCCN.org) for more information. Patients should be considered for vaginal dilators daily during treatment, which can reduce RT doses to sexual organs at risk,¹⁶² and instructed on the symptoms of vaginal stenosis.

The optimal dose and schedule of RT for anal carcinoma continues to be explored and has been evaluated in a number of nonrandomized studies. In one study of patients with early-stage (T1 or Tis) anal canal cancer, most patients were effectively treated with RT doses of 40 to 50 Gy for Tis lesions and 50 to 60 Gy for T1 lesions.¹⁶³ In another study, in



NCCN Guidelines Version 4.2025

Anal Carcinoma

which the majority of patients had stage II/III anal canal cancer, local control of disease was higher in patients who received RT doses greater than 50 Gy than in those who received lower doses (86.5% vs. 34%; $P = .012$).¹⁶⁴ In a third study of patients with T3, T4, or lymph node-positive tumors, RT doses of greater than or equal to 54 Gy administered with limited treatment breaks (<60 days) were associated with increased local control.¹⁶⁵ The effect of further escalation of radiation dose was assessed in the ACCORD 03 trial, with the primary endpoint of colostomy-free survival at 3 years.¹⁴⁷ No benefit was seen with the higher dose of radiation. These results are supported by much earlier results from the RTOG 92-08 trial¹⁶⁶ and suggest that doses of greater than 59 Gy provide no additional benefit to individuals with anal cancer. The randomized, phase 2 DECREASE study (NCT04166318) is currently looking at how well lower-dose chemoRT works in comparison to standard-dose chemoRT for patients with stage I or IIA anal cancer.¹⁶⁷ Patients on this study are randomized to either 28 fractions (standard-dose) or 20 or 23 fractions (deintensified dose) of intensity-modulated radiation therapy (IMRT). Study completion is expected in 2029.

There is evidence that treatment interruptions, either planned or required by treatment-related toxicity, can compromise the effectiveness of treatment.¹¹⁶ In the phase II RTOG 92-08 trial, a planned 2-week treatment break in the delivery of chemoRT to individuals with anal cancer was associated with increased locoregional failure rates and lower colostomy-free survival rates when compared to patients who only had treatment breaks for severe skin toxicity,¹⁶⁸ although the trial was not designed for that particular comparison. In addition, the absence of a planned treatment break in the ACT II trial was considered to be at least partially responsible for the high colostomy-free survival rates observed in that study (74% at 3 years).¹⁴³ A post hoc analysis from the ACT II trial revealed worse outcomes if the planned RT dose was

extended to more than 42 days, with a significant increase in the risk of PFS event ($P = .01$) and worse OS ($P = .006$).¹⁶⁹ Although results of these and other studies have supported the benefit of delivery of chemoRT over shorter time periods,¹⁷⁰⁻¹⁷² treatment breaks in the delivery of chemoRT are required in up to 80% of patients since chemoRT-related toxicities are common.¹⁷² For example, it has been reported that one-third of individuals receiving primary chemoRT for anal carcinoma at RT doses of 30 Gy in 3 weeks develop acute anoproctitis and perineal dermatitis, increasing to one-half to two-thirds of patients when RT doses of 54 to 60 Gy are administered in 6 to 7 weeks.⁸³

Some of the reported late side effects of chemoRT include increased frequency and urgency of defecation, chronic perineal dermatitis, dyspareunia, and impotence.^{173,174} In some cases, severe late RT complications, such as anal ulcers, stenosis, and necrosis, may necessitate surgery involving colostomy.¹⁷⁴ In addition, results from a retrospective cohort study of data from the SEER registry showed the risk of subsequent pelvic fracture to be 3-fold higher in female patients ≥65 years undergoing RT for anal cancer compared with female patients of the same age with anal cancer who did not receive RT.¹⁷⁵

An increasing body of literature suggests that toxicity can be reduced with advanced radiation delivery techniques.^{116,176-186} IMRT utilizes detailed beam shaping to target specific volumes and limit the exposure of normal tissue.¹⁸⁵ Multiple pilot studies have demonstrated reduced toxicity while maintaining local control using IMRT. For example, in a cross-study comparison of a multicenter study of 53 patients with anal cancer treated with concurrent 5-FU/mitomycin chemotherapy and IMRT compared to patients in the 5-FU/mitomycin arm of the randomized RTOG 98-11 study, which used conventional 3-D RT, the rates of grade 3/4 dermatologic toxicity were 38%/0% for patients



NCCN Guidelines Version 4.2025

Anal Carcinoma

treated with IMRT compared to 43%/5% for those undergoing conventional RT.^{100,185} No decrease in treatment effectiveness or local control rates was observed with use of IMRT, although the small sample size and short duration of follow-up limit the conclusions drawn from such a comparison. In one retrospective comparison between IMRT and conventional radiotherapy, IMRT was less toxic and showed better efficacy in 3-year OS, locoregional control, and PFS.¹⁸⁷ In a larger retrospective comparison, no significant differences in local recurrence-free survival, distant metastasis-free survival, colostomy-free survival, and OS at 2 years were seen between patients receiving IMRT and those receiving 3-D conformal radiotherapy, despite the fact that the IMRT group had a higher average N stage.¹⁸⁸

RTOG 0529 was a prospective clinical trial investigating if dose-painted IMRT/5-FU/mitomycin could decrease the rate of gastrointestinal and genitourinary adverse effects compared to patients treated with conventional radiation/5-FU/mitomycin from RTOG 98-11. This trial did not meet its primary endpoint of reducing grade 2+ combined acute genitourinary and gastrointestinal adverse events by 15% compared to conventional radiation on RTOG 98-11.¹⁸⁹ Of 52 evaluable patients, the grade 2+ combined acute adverse event rate was 77%; the rate in RTOG 98-11 was also 77%. However, significant reductions were seen in grade 2+ hematologic events (73% vs. 85%; $P = .032$), grade 3+ gastrointestinal events (21% vs. 36%; $P = .008$), and grade 3+ dermatologic events (23% vs. 49%; $P < .0001$). Subsequently, long-term outcomes and toxicities of individuals with anal cancer treated with dose-painted IMRT as per RTOG 0529 have been reported.^{190,191} Of 99 eligible patients identified in the 2017 publication, 92% had a clinically complete response after a median follow-up of 49 months.¹⁹¹ The 4-year OS was 85.5% and the 4-year event-free survival was 75.5%. The rate of grade ≥ 2 non-hematologic late toxicities was 15%. In a longer-term follow-up with 52 eligible patients, the 8-year OS was 68% and the

8-year disease-free survival was 62%.¹⁹⁰ The rate of grade 2 late adverse events was 55%, 16% for grade 3, 0 for grade 4, and 4% for grade 5 events.

A retrospective cohort study using the 2014 linkage of the SEER-Medicare database showed that IMRT is associated with higher total costs than 3-D conformal radiation (median total cost, \$35,890 vs. \$27,262; $P < .001$), but unplanned health care utilization costs (ie, hospitalizations and emergency department visits) are higher for those receiving conformal radiation (median, \$711 vs. \$4,957 at 1 year; $P = .02$).¹⁹²

Recommendations regarding RT doses follow the multifield technique used in the RTOG 98-11 trial.¹⁰⁰ After clinical and radiologic staging, CT-based simulation is performed for radiation treatment planning. If available, MRI pelvis, FDG-PET/CT, or FDG-PET/ MRI at the time of simulation may be helpful to define local and regional target structures. All patients should receive a minimum RT dose of 45 Gy to the primary cancer. The recommended initial RT dose is 30.6 Gy to the pelvis, anus, perineum, and inguinal nodes; there should be attempts to reduce the dose to the femoral heads. Field reduction off the superior field border and node-negative inguinal nodes is recommended after delivery of 30.6 Gy and 36 Gy, respectively. For patients treated with an anteroposterior/posteroanterior (AP/PA) rather than multifield technique, the dose to the lateral inguinal region should be brought to the minimum dose of 36 Gy using an anterior electron boost matched to the PA exit field. Patients with T1-2 lesions should receive an additional boost of 9 to 14 Gy for a total of 45 Gy. For patients with T1-2 lesions with residual disease after receiving 45 Gy dose, T3-4 lesions, or N1 lesions, additional 5.4–14.4 Gy should be given in 1.8–2 Gy daily fractions for a total dose of 50.4–59.4 Gy. The consensus of the Panel is that IMRT is preferred over 3-D conformal RT in the treatment of anal carcinoma.¹⁹³



NCCN Guidelines Version 4.2025

Anal Carcinoma

IMRT requires expertise and careful target design to avoid reduction in local control by marginal miss.¹¹⁶ The clinical target volumes for anal cancer used in the RTOG 0529 trial have been described in detail.¹⁹³

Also see

<https://www.nrgoncology.org/Portals/0/Scientific%20Program/CIRO/Atlas/AnorectalContouringGuidelines.pdf> for more details of the contouring atlas defined by RTOG.

For individuals with previously untreated anal cancer who present with synchronous local and metastatic disease, chemoRT to the primary site can be considered for local control following first-line chemotherapy, as described in these guidelines. For recurrence in the primary site or nodes after previous chemoRT, surgery should be performed if possible, and, if not, palliative chemoRT can be considered based on symptoms, extent of recurrence, and prior treatment.

Surgical Management

Local excision is used for anal cancer in two situations. The first is for superficially invasive squamous cell carcinoma (SISCCA), which is defined as anal cancer that has been completely excised, with ≤ 3 -mm basement membrane invasion and a maximal horizontal spread of ≤ 7 mm (T1,NX).¹⁹⁴ SISCCA are generally found incidentally in the setting of a biopsy or excision of what is thought to be a benign lesion such as a condyloma, hemorrhoid, or anal skin tag. Such lesions are being seen with increasing frequency because anal cancer screening in high-risk populations is becoming more common. For SISCCA that are noted to have histologically negative margins in carefully selected patients followed by an experienced provider and/or team, local excision alone with a structured surveillance plan may represent adequate treatment. A careful surveillance plan is necessary as observational studies have reported detection of HSIL in 74% of patients following local excision.¹⁹⁵ A retrospective study described characteristics, treatment, and

outcomes of 17 patients with completely excised invasive anal cancer, seven of whom met the criteria for classification as superficially invasive.¹⁹⁶ Those with positive margins (≤ 2 mm for anal canal cancer and < 1 cm for perianal cancer) received local radiation, and all patients underwent surveillance. After a median follow-up of 45 months, no differences were seen in 5-year OS (100% for the entire cohort) or 5-year cancer recurrence-free survival rates (87% for the entire cohort) between the superficially invasive and invasive groups.

Local excision is also used for T1,N0, well-differentiated or select T2,N0 perianal (anal margin) cancer that does not involve the sphincter (also see *Recommendations for the Primary Treatment of Perianal Cancer*, below). In these cases, a 1-cm margin is recommended. A retrospective cohort study that included 2243 adults from the National Cancer Database diagnosed with T1,N0 anal canal cancer between 2004 and 2012 found that the use of local excision in this population increased over time (17.3% in 2004 to 30.8% in 2012; $P < .001$).¹⁹⁷ No significant difference in 5-year OS was seen based on management strategy (85.3% for local excision; 86.8% for chemoRT; $P = .93$). Many patients with T1 or selected T2 perianal cancers will have concomitant HSIL of the anal canal, therefore it is important to look for such anal canal involvement when conservative management (local excision) is being considered.

Radical surgery in anal cancer (APR) is reserved for local recurrence or disease persistence (see *Treatment of Locally Progressive or Recurrent Anal Carcinoma*, below).

Treatment of Anal Cancer in People with HIV/AIDS

As discussed above (see *Risk Factors*), PWH have been reported to be at increased risk for anal carcinoma.^{18,28-31} Some evidence suggests that ART may be associated with a decrease in the incidence of high-grade AIN and its progression to anal cancer.^{35,198} However, the



NCCN Guidelines Version 4.2025

Anal Carcinoma

incidence of anal cancer in PWH has not decreased much, if at all, over time.^{27,29,31,34}

Most evidence regarding outcomes in PWH with anal cancer comes from retrospective comparisons, a few of which found worse outcomes in PWH.¹⁹⁹⁻²⁰¹ For example, a cohort comparison of 40 PWH with anal canal cancer and 81 patients who were HIV-negative with anal canal cancer found local relapse rates to be four times higher in PWH at 3 years (62% vs. 13%) and found significantly higher rates of severe acute skin toxicity for PWH.²⁰⁰ However, no differences in rates of complete response or 5-year OS were observed between the groups in that study. Another systematic review and meta-analysis of 40 studies including 3720 patients with localized squamous cell carcinoma of the anus who were treated with chemoRT, 34% of whom were HIV-positive, found a greater risk of grade 3 and higher cutaneous toxicities (RR = 1.34), and worse 3-year DFS (RR = 1.32) and OS (RR = 1.77) rates, in PWH compared to those who were HIV-negative.²⁰¹

Most studies, however, have found outcomes to be similar in PWH and individuals who were HIV-negative.²⁰²⁻²⁰⁹ In a retrospective cohort study of 1184 veterans diagnosed with squamous cell carcinoma of the anus between 1998 and 2004 (15% of whom tested positive for HIV), no differences with respect to receipt of treatment or 2-year survival rates were observed when the group of PWH was compared with the group of patients testing negative for HIV.²⁰⁴ Another study of 36 consecutive patients with anal cancer including 19 immunocompetent and 17 patients who were immunodeficient (14 PWH) showed no difference in the efficacy or toxicity of chemoRT.²⁰⁸ A population-based study of almost 2 million individuals with cancer, including 6459 PWH, found no increase in cancer-specific mortality for anal cancer in PWH.²¹⁰ Although the numbers of PWH in these studies have been small, the efficacy and safety results appear similar regardless of HIV status.

Overall, the Panel believes that PWH who have anal cancer should be treated as per these guidelines and that modifications to treatment of anal cancer should not be made solely based on HIV status. Additional considerations for PWH who have anal cancer are outlined in the NCCN Guidelines for Cancer in People with HIV (available at www.NCCN.org), including the use of normal tissue-sparing radiation techniques, the consideration of non-malignant causes for lymphadenopathy, and the need for more frequent post-treatment surveillance anoscopy for PWH. Poor performance status in PWH and anal cancer may be from HIV, cancer, or other causes. The reason for poor performance status should be considered when making treatment decisions. Treatment with ART may improve poor performance status related to HIV.

Recommendations for the Primary Treatment of Anal Canal Cancer

Currently, concurrent chemoRT is the recommended primary treatment for patients with non-metastatic anal canal cancer as well as for patients with positive para-aortic lymph nodes that can be included in the radiation field, although only limited retrospective data support use in this setting.²¹¹ Mitomycin/5-FU or mitomycin/capecitabine is administered concurrently with radiation.^{100,139-141} Alternatively, 5-FU/cisplatin can be given with concurrent radiation (category 2B).²¹² Most studies have delivered 5-FU as a protracted 96- to 120-hour infusion during the first and fifth weeks of RT, and bolus injection of mitomycin is typically given on the first or second day of the 5-FU infusion.⁸³ Capecitabine is given orally, Monday through Friday, on each day that RT is given, for 4 or 6 weeks, with bolus injection of mitomycin and concurrent radiation.^{139,141}

An analysis of the National Cancer Database found that only 61.5% of patients with stage I anal canal cancer received chemoRT as recommended in these guidelines.²¹³ Patients who were male, aged ≥70 years, had smaller or lower-grade tumors, or who had been evaluated



NCCN Guidelines Version 4.2025

Anal Carcinoma

at academic facilities were more likely than others to be treated with excision alone. In a separate analysis of the National Cancer Database, 88% of patients with stage II/III anal canal cancer received chemoRT.²¹⁴ Males, Black patients, those with multiple comorbidities, and those treated in academic facilities were less likely to receive combined modality treatment.

RT is associated with significant side effects. Patients should be counseled on infertility risks and given information regarding sperm, oocyte, egg, or ovarian tissue banking prior to treatment. In addition, patients should be considered for vaginal dilators and should be instructed on the symptoms of vaginal stenosis.

Recommendations for the Primary Treatment of Perianal Cancer

Perianal lesions can be treated with either local excision or chemoRT depending on the clinical stage. Primary treatment for patients with T1,N0 well-differentiated or select smaller T2,N0 perianal (anal margin) cancer that does not involve the sphincter is by local excision with adequate margins. The ASCRS defines an adequate margin as 1 cm.⁶⁰ If the margins are not adequate, re-excision is the preferred treatment option. Local RT with or without continuous infusion 5-FU/mitomycin, mitomycin/capecitabine, or 5-FU/cisplatin (category 2B) can be considered as alternative treatment options when surgical margins are inadequate. For all other perianal cancers, the treatment options are the same as for anal canal cancer (see above).^{100,139-141,212}

Surveillance Following Primary Treatment

Following primary treatment of non-metastatic anal cancer, the surveillance and follow-up treatment recommendations for perianal and anal canal cancer are the same. Patients are re-evaluated by DRE between 8 and 12 weeks after completion of chemoRT. Following re-evaluation, patients are classified according to whether they have a

complete remission of disease, persistent disease, or progressive disease. Patients with persistent disease but without evidence of progression may be managed with close follow-up (in 4 weeks) to see if further regression occurs.

The National Cancer Research Institute's ACT II study compared different chemoRT regimens and found no difference in OS or PFS.¹⁴³ Interestingly, 72% of patients in this trial who did not show a complete response at 11 weeks from the start of treatment had achieved a complete response by 26 weeks. 5-year survival was superior in patients who achieved complete response at 26 weeks.²¹⁵ Based on these results, the Panel believes it may be appropriate to follow patients who have not achieved a complete clinical response with persistent anal cancer for up to 6 months after completion of radiation and chemotherapy, as long as there is no evidence of progressive disease during this period of follow-up. Persistent disease may continue to regress for up to 6 months from the start of treatment, and APR can thereby be avoided in some patients. In these patients, observation and re-evaluation should be performed at 3-month intervals. The Panel recommends against the use of FDG-PET/CT imaging as part of this re-evaluation strategy due to concerns for false-positivity from local inflammation from RT leading to unnecessary surgeries. If biopsy-proven disease progression occurs, further intensive treatment is indicated (see *Treatment of Locally Progressive or Recurrent Anal Carcinoma*, below).

Although a clinical assessment of progressive disease requires histologic confirmation, patients can be classified as having a complete remission without biopsy verification if clinical evidence of disease is absent. The Panel recommends that these patients undergo evaluation every 3 to 6 months for 5 years, including DRE and inguinal node palpation. Anoscopic evaluation is recommended every 6 to 12 months



NCCN Guidelines Version 4.2025

Anal Carcinoma

for 3 years. Annual chest, abdomen, and pelvis CT with contrast or chest CT without contrast and abdomen/pelvis MRI with contrast is recommended for 3 years for patients who initially had stage II–III disease.

Treatment of Locally Progressive or Recurrent Anal Carcinoma

Despite the effectiveness of chemoRT in the primary treatment of anal carcinoma, rates of locoregional failure of 10% to 30% have been reported.^{216,217} Some of the disease characteristics that have been associated with higher recurrence rates following chemoRT include higher T stage and higher N stage (also see the section on *Prognostic Factors*, above).²¹⁸

Evidence of progression found on DRE should be followed by biopsy as well as restaging with CT and/or FDG-PET/CT imaging. Patients with biopsy-proven locally progressive disease are candidates for radical surgery with an APR and colostomy.²¹⁷ In an attempt to avoid surgery, the use of immunotherapy with nivolumab or pembrolizumab may be considered prior to APR (category 2B) as some patients may have a good response, however it should be noted that this approach is based on institutional experience only and there are currently no published data supporting its use in this setting of otherwise curative intent surgery.

A multicenter retrospective cohort study looked at the cause-specific colostomy rates in 235 patients with anal cancer who were treated with radiotherapy or chemoRT from 1995 to 2003.²¹⁹ The 5-year cumulative incidence rates for tumor-specific and therapy-specific colostomy were 26% (95% CI, 21–32) and 8% (95% CI, 5–12), respectively. Larger tumor size (>6 cm) was a risk factor for tumor-specific colostomy, while local excision prior to radiotherapy was a risk factor for therapy-specific colostomy. However, it should be noted that these patients were treated

with older chemotherapy and RT regimens, which could account for these high colostomy rates.²²⁰

In studies involving a minimum of 25 patients undergoing an APR for anal carcinoma, 5-year survival rates of 39% to 66% have been observed.^{216,217,221–225} Complication rates were reported to be high in some of these studies. Factors associated with worse prognosis following APR include an initial presentation of node-positive disease and RT doses <55 Gy used in the treatment of primary disease.²¹⁷

The general principles for APR technique are similar to those for distal rectal cancer and include the incorporation of meticulous total mesorectal excision (TME). However, APR for anal cancer may require wider lateral perianal margins than are required for rectal cancer. A retrospective analysis of the medical records of 14 individuals who received intraoperative radiation therapy (IORT) during APR revealed that IORT is unlikely to improve local control or to give a survival benefit.²²⁶

Because of the necessary exposure of the perineum to radiation, individuals with anal cancer are prone to poor perineal wound healing. It has been shown that for patients undergoing an APR that was preceded by RT, closure of the perineal wound using rectus abdominis myocutaneous flap reconstruction results in decreased perineal wound complications.^{227,228} Reconstructive tissue flaps for the perineum, such as the vertical rectus or local myocutaneous flaps, should therefore be considered for patients with anal cancer undergoing an APR.

Inguinal node dissection is recommended for recurrence in that area and for patients who require an APR but have already received groin radiation. Inguinal node dissection can be performed with or without an APR depending on whether disease is isolated to the groin or has



NCCN Guidelines Version 4.2025

Anal Carcinoma

occurred in conjunction with recurrence or persistence at the primary site.

Patients who develop inguinal node metastasis who do not undergo an APR can be considered for palliative RT to the groin with or without 5-FU/mitomycin or mitomycin/capecitabine if no prior RT to the groin was given. Radiation therapy technique and doses are dependent on dosing and technique of prior treatment (see the guidelines above). If RT was given previously, 5-FU/cisplatin chemotherapy may be given (category 2B).

Surveillance Following Treatment of Recurrence

Following APR, patients should undergo re-evaluation every 3 to 6 months for 5 years, including clinical evaluation for nodal metastasis (ie, inguinal node palpation). In addition, it is recommended that these patients undergo annual chest, abdomen, and pelvis CT with contrast or chest CT without contrast and abdomen/pelvis MRI with contrast for 3 years. In one retrospective study of 105 patients with anal canal carcinoma who had an APR between 1996 and 2009, the overall recurrence rate following APR was 43%.²²⁹ Those with T3/4 tumors or involved margins were more likely to experience recurrence. The 5-year survival rate after APR has been reported to be 60% to 64%.^{229,230}

Following treatment of inguinal node recurrence, patients should have a DRE and inguinal node palpation every 3 to 6 months for 5 years. In addition, anoscopy every 6 to 12 months and annual chest, abdomen, and pelvis CT with contrast or chest CT without contrast and abdomen/pelvis MRI with contrast are recommended for 3 years.

Treatment of Metastatic Anal Cancer

It has been reported that the most common sites of anal cancer metastasis outside of the pelvis are the liver, lung, and extrapelvic lymph nodes.²³¹ Since anal carcinoma is a rare cancer and only 10% to

20% of individuals with anal carcinoma present with extrapelvic metastatic disease,²³¹ only limited data are available on this population of patients. Despite this fact, evidence indicates that systemic therapy has some benefit in individuals with metastatic anal carcinoma.

Palliative chemoRT to the primary site can be administered following upfront chemotherapy for local control of a symptomatic bulky primary. In fact, an analysis of the National Cancer Database reported that individuals with newly diagnosed metastatic anal cancer who received definitive pelvic RT in addition to chemotherapy had longer median OS than those who received chemotherapy alone (21.3 vs. 15.9 months; HR, 0.70; 95% CI, 0.61–0.81; $P < .001$).²³² A retrospective analysis of 106 patients with squamous cell carcinoma reported that resection or ablation of liver metastases can result in long-term survival and that individuals with anal cancer had better outcomes than those with non-anal squamous cell carcinoma, although this approach is not currently included in the NCCN Guidelines® for Anal Carcinoma.²³³

First-Line Treatment of Metastatic Anal Cancer

Recent studies have demonstrated the efficacy of checkpoint inhibitors in combination with chemotherapy for first-line treatment of metastatic anal cancer. The phase 3 global study POD1UM-303/InterAACT2 (NCT04472429) is investigating the addition of the checkpoint inhibitor, retifanlimab, to the chemotherapy of choice in this study (carboplatin/paclitaxel) and comparing it to chemotherapy alone.²³⁴ This trial is expected to be completed in 2026, but preliminary results show that the primary endpoint was met, with an improved median PFS in patients treated with chemotherapy and retifanlimab compared to those treated with chemotherapy alone (9.30 [95% CI, 7.5–11.3] and 7.39 months [95% CI, 7.1–7.7], respectively; HR = 0.63; $P = .0006$). The secondary endpoint of OS also trends favorable, with 29.2 months (95% CI, 24.2–not estimable [NE]) for those treated with the addition of



NCCN Guidelines Version 4.2025

Anal Carcinoma

retifanlimab versus 23.0 months (95% CI, 15.1–27.9) for patients that did not have retifanlimab in their combination treatment. Based on these data, the Panel has added carboplatin/paclitaxel with retifanlimab as the preferred regimen for first-line treatment of metastatic anal cancer. Similarly, NCT04444921 is a randomized, phase 3 trial comparing chemotherapy alone (carboplatin and paclitaxel) to chemotherapy plus nivolumab for treatment-naïve metastatic anal cancer.²³⁵ This study has 205 participants and is expected to complete in 2026, therefore this combination regimen is not currently listed in these guidelines.

The combination regimen of carboplatin and paclitaxel was initially researched in the phase II International Multicentre InterAACT study.²³⁶ In this trial, 91 patients with previously untreated, unresectable, locally recurrent or metastatic anal squamous cell carcinoma were randomized to either carboplatin plus paclitaxel or cisplatin plus 5-FU. While response rates were similar between carboplatin plus paclitaxel and cisplatin plus 5-FU (59% and 57%, respectively), carboplatin plus paclitaxel showed lower toxicity compared to cisplatin plus 5-FU (71% vs. 76% grade ≥3 toxicity and 36% vs. 62% [$P = .016$] serious adverse events). Median PFS and OS were 8.1 months and 20 months for carboplatin plus paclitaxel and 5.7 months and 12.3 months for cisplatin plus 5-FU (HR for OS, 2.0; 95% CI, 1.15–3.47; $P = .014$).²³⁶ The results from the InterAACT trial are in agreement with older studies that showed that chemotherapy with a fluoropyrimidine-based regimen plus cisplatin^{212,237–239} or a platinum-based therapy plus paclitaxel^{238,240,241} benefited some patients with metastatic anal carcinoma. Due to the current results of the PODIUM 303/InterAACT2 study showing improved PFS with addition of retifanlimab, the Panel has added carboplatin and paclitaxel as other recommended regimen for first-line treatment of metastatic anal cancer, with the retifanlimab combination being preferred.

Other recommended treatment options include 5-FU, leucovorin, and cisplatin (FOLFCIS); 5-FU, leucovorin, and oxaliplatin (FOLFOX); 5-FU plus cisplatin (category 2B reflecting its similar efficacy, but higher toxicity, when compared to carboplatin plus paclitaxel in a randomized trial); or modified docetaxel, cisplatin, and 5-FU (DCF, category 2B). A retrospective study of 53 patients with advanced anal squamous cell carcinoma who received FOLFCIS as first-line therapy showed that this regimen was safe and effective in this patient population. The response rate was 48%, PFS was 7.1 months, and OS was 22.1 months.²⁴² The safety of FOLFOX in individuals with anal cancer has been demonstrated in a case report.²⁴³ Despite the limited data for FOLFOX in this setting, the Panel added it based on consensus and its current use as a standard option at many NCCN Member Institutions. With use of FOLFOX, the Panel recommends strong consideration of discontinuation of oxaliplatin after 3 to 4 months (or sooner for unacceptable neurotoxicity) while maintaining other agents until time of disease progression.²⁴⁴ Oxaliplatin may be reintroduced if it was discontinued for neurotoxicity rather than for disease progression.

DCF is another regimen that has been evaluated for metastatic anal cancer.^{245,246} A single-arm phase II trial evaluated this regimen in individuals with previously untreated, advanced anal squamous cell carcinoma. This trial demonstrated the efficacy of DCF (both standard and modified regimens) in this setting and reported better tolerability of modified DCF compared to the standard regimen.²⁴⁵ The median PFS was 10.7 months for the standard DCF regimen and 11.0 months for the modified regimen. For the standard regimen, 83% of patients had at least one grade 3–4 AE, while 53% had at least one grade 3–4 adverse event when treated with modified DCF. The most common grade 3–4 adverse events were neutropenia, diarrhea, asthenia, anemia, lymphopenia, mucositis, and vomiting. Based on these results, the Panel added modified DCF as an option for metastatic anal cancer, with



NCCN Guidelines Version 4.2025

Anal Carcinoma

the category 2B designation reflecting concerns voiced by some Panel members about potentially higher toxicity with modified DCF compared to the other regimens recommended for metastatic anal cancer.

Second-Line Treatment of Metastatic Anal Cancer

A single-arm, multicenter phase 2 trial assessed the safety and efficacy of the anti-PD-1 antibody nivolumab for refractory metastatic anal cancer.²⁴⁷ Two complete responses and seven partial responses were seen among the 37 enrolled participants who received at least one dose, for a response rate of 24% (95% CI, 15–33). The KEYNOTE-028 trial is a multi-cohort, phase 1b trial of the anti-PD-1 antibody pembrolizumab in 24 patients with programmed cell death ligand 1 (PD-L1)–positive advanced squamous cell carcinoma of the anal canal.²⁴⁸ Four partial responses were seen, for a response rate of 17% (95% CI, 5–37), and 10 patients (42%) had stable disease, for a disease control rate of 58%. In both trials, toxicities were manageable, with 13% and 17% experiencing grade 3 adverse events with nivolumab and pembrolizumab, respectively.^{247,248} The phase II KEYNOTE-158 study investigated the use of pembrolizumab in individuals with noncolorectal microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) cancers, including patients with anal cancer (cohort A).^{249,250} A total of 112 patients with anal cancer were enrolled and treated, 67% of whom had PD-L1-positive disease.²⁵⁰ A total of 11% of patients (95% CI, 6–18) had an objective response, with responses in 15% (95% CI, 8–25) of patients with PD-L1-positive disease and in 3% (95% CI, 0–17) with PD-L1-negative disease. Serious treatment-related adverse events were noted in 11% of patients, with 25% of patients having immune-mediated events. This study demonstrated the clinical benefit of pembrolizumab for individuals with previously treated advanced anal squamous cell carcinoma.

The phase 2 PODIUM-202 trial investigated retifanlimab as a second-line agent for advanced or metastatic squamous cell carcinoma of the anal canal that progressed following platinum-based chemotherapy.²⁵¹ The primary endpoint was overall rate response (ORR) and secondary endpoints were duration of response (DOR), PFS and OS in the 94 enrolled patients. At a median follow-up of 7.1 months, the ORR was 13.8% (95% CI, 7.6%–22.5%) with one patient having a complete response, and 12 receiving partial responses. Additionally, the median DOR was 9.5 months, and the median PFS and OS were 2.3 months (95% CI, 1.9–3.6) and 10.1 (95% CI, 7.9–NE), respectively. Based on these data, the Panel recommends retifanlimab as a treatment option for second-line and subsequent therapy for advanced or metastatic squamous cell carcinoma of the anal canal. Another phase 2 clinical trial (NCT02314169) is underway investigating the efficacy and safety of nivolumab, with or without ipilimumab, for patients with refractory metastatic anal canal cancer.²⁵² This trial has an enrollment of 37 participants and is expected to complete in March 2026. Other checkpoint inhibitor immunotherapy agents such as: cemiplimab-rwlc, dostarlimab-gxly, tislelizumab-jsgr, and toripalimab-tpzi are also recommended by the Panel based on extrapolation from colon and rectal cancers. However, there are no current studies of these agents in anal cancer.

Although further studies of PD-1/PD-L1 inhibitors are warranted, the Panel added nivolumab, pembrolizumab, cemiplimab-rwlc, dostarlimab-gxly, tislelizumab-jsgr, and toripalimab-tpzi as preferred options for individuals with metastatic anal cancer who have progressed on first-line chemotherapy. Microsatellite instability (MSI)/mismatch repair (MMR) testing is not required. MSI is uncommon in anal cancer,²⁵³ and as discussed above, responses to PD-1/PD-L1 inhibitors occur in 20% to 24% of patients.^{247,248} Anal cancers may be responsive to PD-1/PD-



NCCN Guidelines Version 4.2025

Anal Carcinoma

L1 inhibitors because they often have high PD-L1 expression and/or a high tumor mutational load despite being microsatellite stable (MSS).²⁵³

The Panel includes chemotherapy agents as options in second line therapy if not previously given in first line, but also notes that platinum-based chemotherapy should not be given in second line if disease progressed on platinum-based therapy in first line.

Survivorship

The Panel recommends that a prescription for survivorship and transfer of care to the primary care physician be written.²⁵⁴ The oncologist and primary care provider should have defined roles in the surveillance period, with roles communicated to the patient. The care plan should include an overall summary of treatments received, including surgeries, radiation treatments, and chemotherapy. The possible expected time to resolution of acute toxicities, long-term effects of treatment, and possible late sequelae of treatment should be described. Finally, surveillance and health behavior recommendations should be part of the care plan.

Disease-preventive measures, such as immunizations; early disease detection through periodic screening for second primary cancers (eg, breast, cervical, prostate cancers); and routine good medical care and monitoring are recommended (see the NCCN Guidelines for Survivorship, available at www.NCCN.org). Additional health monitoring should be performed as indicated under the care of a primary care physician. Survivors are encouraged to maintain a therapeutic relationship with a primary care physician throughout their lifetime.²⁵⁵

Other recommendations include monitoring for late sequelae of anal cancer or the treatment of anal cancer. Late toxicity from pelvic radiation can include bowel dysfunction (ie, increased stool frequency, fecal incontinence, flatulence, rectal urgency), urinary dysfunction, and

sexual dysfunction (ie, impotence, dyspareunia, vaginal stenosis, vaginal dryness, reduced libido).²⁵⁶⁻²⁶⁰ Anal cancer survivors also report significantly reduced global quality of life, with increased frequency of somatic symptoms including fatigue, dyspnea, nausea, appetite loss, pain, and insomnia.^{256,260-262} Therefore, survivors of anal cancer should be screened regularly for distress.

The NCCN Guidelines for Survivorship (available at www.NCCN.org) provide screening, evaluation, and treatment recommendations for common consequences of cancer and cancer treatment to aid health care professionals who work with survivors of adult-onset cancer in the post-treatment period, including those in specialty cancer survivor clinics and primary care practices. These guidelines include many topics with potential relevance to survivors of anal cancer, including anxiety, depression, and distress; cognitive dysfunction; fatigue; pain; sexual dysfunction; sleep disorders; healthy lifestyles; and immunizations. Concerns related to employment, insurance, and disability are also discussed.

Summary

The NCCN Anal Carcinoma Guidelines Panel believes that a multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary for treating individuals with anal carcinoma.

Recommendations for the primary treatment of perianal cancer and anal canal cancer are very similar and include chemoRT in most cases. The exception is small, well or moderately differentiated perianal lesions and superficially invasive lesions, which can be treated with margin-negative local excision alone. Follow-up clinical evaluations are recommended for all individuals with anal carcinoma because additional curative-intent treatment is possible. Patients with biopsy-proven evidence of locally



NCCN Guidelines Version 4.2025

Anal Carcinoma

recurrent or persistent disease following primary treatment should undergo an APR with groin dissection if there is clinical evidence of inguinal nodal metastasis. Patients with a regional recurrence in the inguinal nodes can be treated with an inguinal node dissection, with consideration of RT with or without chemotherapy if no prior RT to the groin was given. Patients with evidence of extrapelvic metastatic disease should be treated with systemic therapy. The Panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.



NCCN Guidelines Version 4.2025

Anal Carcinoma

References

1. Siegel RL, Kratzer TB, Giaquinto AN, et al. Cancer statistics, 2025. *CA Cancer J Clin* 2025;75:10-45. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/39817679>.
2. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. *J Natl Cancer Inst* 2013;105:175-201. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23297039>.
3. Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. *Cancer* 2004;101:281-288. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15241824>.
4. Nelson RA, Levine AM, Bernstein L, et al. Changing patterns of anal canal carcinoma in the United States. *J Clin Oncol* 2013;31:1569-1575. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23509304>.
5. Shiels MS, Kreimer AR, Coghill AE, et al. Anal cancer incidence in the United States, 1977-2011: distinct patterns by histology and behavior. *Cancer Epidemiol Biomarkers Prev* 2015;24:1548-1556. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26224796>.
6. Deshmukh AA, Suk R, Shiels MS, et al. Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001-2015. *J Natl Cancer Inst* 2020;112:829-838. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31742639>.
7. Raed A, Zandu M, Sharma A, et al. Anal Squamous Cell Carcinoma: A Growing Threat to Women's Health and Call for Action [abstract]. American College of Gastroenterology Annual Scientific Meeting 2020; Abstract P0399. Available at: https://journals.lww.com/ajg/fulltext/2020/10001/s0180_anal_squamous_cell_carcinoma_a_growing.180.aspx.
8. Glynne-Jones R, Nilsson PJ, Aschele C, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. *Radiother Oncol* 2014;111:330-339. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24947004>.
9. Moureau-Zabotto L, Vendrely V, Abramowitz L, et al. Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). *Dig Liver Dis* 2017;49:831-840. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28610905>.
10. Stewart DB, Gaertner WB, Glasgow SC, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Anal Squamous Cell Cancers (Revised 2018). *Dis Colon Rectum* 2018;61:755-774. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29878949>.
11. PubMed Overview. Available at: <https://pubmed.ncbi.nlm.nih.gov/about/>. Accessed May 28, 2025.
12. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. *Cancer* 2004;101:270-280. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15241823>.
13. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. *N Engl J Med* 1997;337:1350-1358. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9358129>.
14. Jimenez W, Paszat L, Kupets R, et al. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. *Gynecol Oncol* 2009;114:395-398. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19501390>.
15. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. *N Engl J Med* 2000;342:792-800. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10717015>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

16. Sunesen KG, Norgaard M, Thorlacius-Ussing O, Laurberg S. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. *Int J Cancer* 2010;127:675-684. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19960431>.
17. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. *J Natl Cancer Inst* 2000;92:1500-1510. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10995805>.
18. Uronis HE, Bendell JC. Anal cancer: an overview. *Oncologist* 2007;12:524-534. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17522240>.
19. Albuquerque A, Stirrup O, Nathan M, Clifford GM. Burden of anal squamous cell carcinoma, squamous intraepithelial lesions and HPV16 infection in solid organ transplant recipients: A systematic review and meta-analysis. *Am J Transplant* 2020;20:3520-3528. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32343489>.
20. Clifford GM, Georges D, Shiels MS, et al. A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. *Int J Cancer* 2021;148:38-47. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32621759>.
21. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. *Int J Cancer* 2009;124:1626-1636. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19115209>.
22. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. *Int J Cancer* 2009;124:2375-2383. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19189402>.
23. Ouhoumane N, Steben M, Coutlee F, et al. Squamous anal cancer: patient characteristics and HPV type distribution. *Cancer Epidemiol* 2013;37:807-812. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24139594>.
24. Steinau M, Unger ER, Hernandez BY, et al. Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. *J Low Genit Tract Dis* 2013;17:397-403. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23609590>.
25. Human papillomavirus-associated cancers - United States, 2004-2008. *MMWR Morb Mortal Wkly Rep* 2012;61:258-261. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22513527>.
26. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. *J Infect Dis* 1998;177:361-367. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9466522>.
27. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. *Ann Intern Med* 2008;148:728-736. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18490686>.
28. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. *J Natl Cancer Inst* 2009;101:1120-1130. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19648510>.
29. Colon-Lopez V, Shiels MS, Machin M, et al. Anal Cancer Risk Among People With HIV Infection in the United States. *J Clin Oncol* 2018;36:68-75. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29140774>.
30. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. *Lancet* 2007;370:59-67. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17617273>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

31. Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. *Lancet HIV* 2017;4:e495-e504. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28803888>.
32. Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. *Clin Infect Dis* 2012;54:1026-1034. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22291097>.
33. Stier EA, Sebring MC, Mendez AE, et al. Prevalence of anal human papillomavirus infection and anal HPV-related disorders in women: a systematic review. *Am J Obstet Gynecol* 2015;213:278-309. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25797230>.
34. Piketty C, Selinger-Leneman H, Bouvier AM, et al. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. *J Clin Oncol* 2012;30:4360-4366. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23091098>.
35. Libois A, Feoli F, Nkuize M, et al. Prolonged antiretroviral therapy is associated with fewer anal high-grade squamous intraepithelial lesions in HIV-positive MSM in a cross-sectional study. *Sex Transm Infect* 2017;93:15-17. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27030607>.
36. Shing JZ, Engels EA, Austin AA, et al. Survival by sex and HIV status in patients with anal cancer in the USA between 2001 and 2019: a retrospective cohort study. *Lancet HIV* 2024;11:e31-e41. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38081198>.
37. Nuno T, Garcia F. The Lower Anogenital Squamous Terminology Project and its implications for clinical care. *Obstet Gynecol Clin North Am* 2013;40:225-233. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23732027>.
38. Berry JM, Jay N, Cranston RD, et al. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. *Int J Cancer* 2014;134:1147-1155. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23934991>.
39. Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial neoplasia. *Br J Surg* 2005;92:1133-1136. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16044425>.
40. Watson AJ, Smith BB, Whitehead MR, et al. Malignant progression of anal intra-epithelial neoplasia. *ANZ J Surg* 2006;76:715-717. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16916390>.
41. Tinmouth J, Peeva V, Amare H, et al. Progression from perianal high-grade anal intraepithelial neoplasia to anal cancer in HIV-positive men who have sex with men. *Dis Colon Rectum* 2016;59:836-842. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27505112>.
42. Berry JM, Palefsky JM, Jay N, et al. Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. *Dis Colon Rectum* 2009;52:239-247. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19279418>.
43. Jay N. Elements of an anal dysplasia screening program. *J Assoc Nurses AIDS Care* 2011;22:465-477. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22035526>.
44. Palefsky JM, Lee JY, Jay N, et al. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. *N Engl J Med* 2022;386:2273-2282. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35704479>.
45. Barroso LF. Anal cancer screening. *Lancet Oncol* 2012;13:e278-279; author reply e280. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22748260>.
46. Goldstone SE, Johnstone AA, Moshier EL. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. *Dis Colon Rectum* 2014;57:316-323. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24509453>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

47. Palefsky J, Berry JM, Jay N. Anal cancer screening. *Lancet Oncol* 2012;13:e279-280; author reply e280. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22748261>.
48. Park IU, Palefsky JM. Evaluation and management of anal intraepithelial neoplasia in HIV-negative and HIV-positive men who have sex with men. *Curr Infect Dis Rep* 2010;12:126-133. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20461117>.
49. Roark R. The need for anal dysplasia screening and treatment programs for HIV-infected men who have sex with men: a review of the literature. *J Assoc Nurses AIDS Care* 2011;22:433-443. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22035523>.
50. Scholefield JH, Harris D, Radcliffe A. Guidelines for management of anal intraepithelial neoplasia. *Colorectal Dis* 2011;13 Suppl 1:3-10. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21251167>.
51. Wentzensen N. Screening for anal cancer: endpoints needed. *Lancet Oncol* 2012;13:438-440. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22445258>.
52. Chen CC, Chou YY. Predictive value of the anal cytology for detecting anal intraepithelial neoplasia or worse: A systematic review and meta-analysis. *Diagn Cytopathol* 2019;47:307-314. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30605263>.
53. Dias Goncalves Lima F, Viset JD, Leeftang MMG, et al. The Accuracy of Anal Swab-Based Tests to Detect High-Grade Anal Intraepithelial Neoplasia in HIV-Infected Patients: A Systematic Review and Meta-analysis. *Open Forum Infect Dis* 2019;6:ofz191. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31123696>.
54. Goncalves JCN, Macedo ACL, Madeira K, et al. Accuracy of Anal Cytology for Diagnostic of Precursor Lesions of Anal Cancer: Systematic Review and Meta-analysis. *Dis Colon Rectum* 2019;62:112-120. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30451747>.
55. Palefsky JM. Prevention of Anal Cancer in High-Risk Individuals. *JAMA* 2024;332:1663-1664. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/39441567>.
56. Stier EA, Clarke MA, Deshmukh AA, et al. International Anal Neoplasia Society's consensus guidelines for anal cancer screening. *Int J Cancer* 2024;154:1694-1702. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/38297406>.
57. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. 2024. Available at: <https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human?view=full>.
58. Alam NN, White DA, Narang SK, et al. Systematic review of guidelines for the assessment and management of high-grade anal intraepithelial neoplasia (AIN II/III). *Colorectal Dis* 2016;18:135-146. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26559167>.
59. Hartschuh W, Breitkopf C, Lenhard B, et al. S1 guideline: anal intraepithelial neoplasia (AIN) and perianal intraepithelial neoplasia (PAIN). *J Dtsch Dermatol Ges* 2011;9:256-258. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21208377>.
60. Steele SR, Varma MG, Melton GB, et al. Practice parameters for anal squamous neoplasms. *Dis Colon Rectum* 2012;55:735-749. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22706125>.
61. Richel O, de Vries HJ, van Noesel CJ, et al. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. *Lancet Oncol* 2013;14:346-353. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23499546>.
62. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N Engl J Med* 2007;356:1915-1927. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17494925>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

63. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. *BMJ* 2010;341:c3493. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20647284>.

64. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *N Engl J Med* 2007;356:1928-1943. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17494926>.

65. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. *N Engl J Med* 2011;364:401-411. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21288094>.

66. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. *N Engl J Med* 2011;365:1576-1585. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22029979>.

67. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep* 2010;59:626-629. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20508593>.

68. Kreimer AR, Gonzalez P, Katki HA, et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. *Lancet Oncol* 2011;12:862-870. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21865087>.

69. Beachler DC, Kreimer AR, Schiffman M, et al. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. *J Natl Cancer Inst* 2016;108. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26467666>.

70. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. *Lancet Oncol* 2011;13:69-99. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22075171>.

71. Petrosky E, Bocchini JA, Jr., Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. *MMWR Morb Mortal Wkly Rep* 2015;64:300-304. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25811679>.

72. Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. *J Natl Cancer Inst* 2015;107:djv086. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25925419>.

73. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *N Engl J Med* 2015;372:711-723. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25693011>.

74. Restrepo J, Herrera T, Samakoses R, et al. Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety. *Pediatrics* 2023;152. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/37667847>.

75. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2014;63:1-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25167164>.

76. Meites E, Kempe A, Markowitz LE. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep* 2016;65:1405-1408. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27977643>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

77. Kim DK, Riley LE, Harriman KH, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2017. *MMWR Morb Mortal Wkly Rep* 2017;66:136-138. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28182599>.
78. Meites E, Szilagyi PG, Chesson HW, et al. Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep* 2019;68:698-702. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31415491>.
79. HPV vaccine recommendations. *Pediatrics* 2012;129:602-605. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22371460>.
80. Bailey HH, Chuang LT, duPont NC, et al. American Society of Clinical Oncology statement: human papillomavirus vaccination for cancer prevention. *J Clin Oncol* 2016;34:1803-1812. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27069078>.
81. National Cervical Center Coalition. FDA Approves HPV Vaccine for Adults Over 26. Available at: <https://www.nccc-online.org/fda-approves-hpv-vaccine-adults-26/>. Accessed May 28, 2025.
82. Goodman K, Gollub M, Eng C. *AJCC Cancer Staging System: Anus*: American College of Surgeons; 2022.
83. Cummings BJ, Ajani JA, Swallow CJ. Cancer of the anal region. In: DeVita Jr. VT, Lawrence TS, Rosenberg SA, et al., eds. *Cancer: Principles & Practice of Oncology*, Eighth Edition. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008.
84. Greene FC, CC; Fritz, AG; Shah, JP; Winchester, DP. *AJCC Cancer Staging Atlas* (ed 1). NY: Springer New York, NY; 2006.
85. Pandey P. Anal anatomy and normal histology. *Sex Health* 2012;9:513-516. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23380234>.
86. Nivatvongs S, Stern HS, Fryd DS. The length of the anal canal. *Dis Colon Rectum* 1981;24:600-601. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7318624>.
87. Jass JR, Sobin LH. *Histological Typing of Intestinal Tumours*: Springer-Verlag Berlin Heidelberg; 1989.
88. Fenger C, Frisch M, Marti MC, Parc R. Tumours of the anal canal. In: Hamilton SR, Aaltonen LA, eds. *WHO Classification of Tumours, Volume 2: Pathology and Genetics. Tumours of the Digestive System*. Lyon: IARC Press; 2000:145-155.
89. Welton ML, Lambert R, Bosman FT. Tumours of the Anal Canal. In: Bosman FT, Carneiro, F., Hruban, R. H., Theise, N.D., ed. *WHO Classification of Tumours of the Digestive System*. Lyon: IARC; 2010:183-193.
90. Fenger C. Prognostic factors in anal carcinoma. *Pathology* 2002;34:573-578. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12555997>.
91. Oliver GC, Labow SB. Neoplasms of the anus. *Surg Clin North Am* 1994;74:1475-1490. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7985077>.
92. Tabbara SO, Cameron SE, Dvorak J, et al. Protocol for the Reporting of Anal Cytology Specimens. 2023. Available at: <https://documents.cap.org/protocols/Cyto.Anal.1.0.0.0.REL.CAPCP.pdf>.
93. Burgart LJ, Chopp WV, Jain D. Protocol for the Examination of Resection Specimens From Patients With Carcinoma of the Anus. 2022. Available at: <https://documents.cap.org/protocols/Anus.5.0.0.0.REL.CAPCP.pdf>.
94. Edge SBB, D.R.; Compton, C.C.; Fritz, A.G.; Greene, F.L.; Trotti, A., ed *AJCC Cancer Staging Manual* (ed 7th Edition). New York: Springer; 2010.



NCCN Guidelines Version 4.2025

Anal Carcinoma

95. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. 2010. Available at: http://seer.cancer.gov/csr/1975_2007/.

96. Gerard JP, Chapet O, Samiei F, et al. Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. *Cancer* 2001;92:77-84. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11443612>.

97. Gunderson LL, Moughan J, Ajani JA, et al. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. *Int J Radiat Oncol Biol Phys* 2013;87:638-645. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24035327>.

98. Welton ML, Steele SR, Goodman KA, et al. Anus. In: Amin MB, ed. *AJCC Cancer Staging Manual*, Eighth Edition: Springer; 2017.

99. Wade DS, Herrera L, Castillo NB, Petrelli NJ. Metastases to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique. *Surg Gynecol Obstet* 1989;169:238-242. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2672386>.

100. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA* 2008;299:1914-1921. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18430910>.

101. Ajani JA, Winter KA, Gunderson LL, et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. *J Clin Oncol* 2009;27:1116-1121. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19139424>.

102. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and

Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. *J Clin Oncol* 1997;15:2040-2049. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9164216>.

103. Glynne-Jones R, Sebag-Montefiore D, Adams R, et al. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). *Cancer* 2013;119:748-755. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23011911>.

104. Rodel F, Wieland U, Fraunholz I, et al. Human papillomavirus DNA load and p16 expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. *Int J Cancer* 2014;136:278-288. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24839133>.

105. Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, et al. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. *J Clin Oncol* 2014;32:1812-1817. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24821878>.

106. Urbute A, Rasmussen CL, Belmonte F, et al. Prognostic Significance of HPV DNA and p16(INK4a) in Anal Cancer: A Systematic Review and Meta-Analysis. *Cancer Epidemiol Biomarkers Prev* 2020;29:703-710. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32051192>.

107. Parwaiz I, MacCabe TA, Thomas MG, Messenger DE. A Systematic Review and Meta-Analysis of Prognostic Biomarkers in Anal Squamous Cell Carcinoma Treated With Primary Chemoradiotherapy. *Clin Oncol (R Coll Radiol)* 2019;31:e1-e13. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31301958>.

108. U.S. Statistics. HIV.gov; 2025. Available at: <https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics>. Accessed May 28, 2025.



NCCN Guidelines Version 4.2025

Anal Carcinoma

109. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. *J Acquir Immune Defic Syndr* 2005;39:446-453. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16010168>.
110. Chiao EY, Dezube BJ, Krown SE, et al. Time for oncologists to opt in for routine opt-out HIV testing? *JAMA* 2010;304:334-339. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20639567>.
111. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep* 2006;55:1-17; quiz CE11-14. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16988643>.
112. Bhuvana NJ, Glynn-Jones R, Sonoda L, et al. To PET or not to PET? That is the question. Staging in anal cancer. *Ann Oncol* 2012;23:2078-2082. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22294527>.
113. Caldarella C, Annunziata S, Treglia G, et al. Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis. *Scientific World Journal* 2014;196068. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24672298>.
114. Cotter SE, Grigsby PW, Siegel BA, et al. FDG-PET/CT in the evaluation of anal carcinoma. *Int J Radiat Oncol Biol Phys* 2006;65:720-725. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16626889>.
115. Mistrangelo M, Pelosi E, Bello M, et al. Role of positron emission tomography-computed tomography in the management of anal cancer. *Int J Radiat Oncol Biol Phys* 2012;84:66-72. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22592047>.
116. Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. *J Natl Compr Canc Netw* 2010;8:123-129. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20064294>.
117. Trautmann TG, Zuger JH. Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. *Mol Imaging Biol* 2005;7:309-313. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16028002>.
118. Mahmud A, Poon R, Jonker D. PET imaging in anal canal cancer: a systematic review and meta-analysis. *Br J Radiol* 2017;90:20170370. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28972796>.
119. Jones M, Hruby G, Solomon M, et al. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. *Ann Surg Oncol* 2015;22:3574-3581. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25652048>.
120. Albertsson P, Alverbratt C, Liljegren A, et al. Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysis. *Crit Rev Oncol Hematol* 2018;126:6-12. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29759568>.
121. Sekhar H, Zwahlen M, Trelle S, et al. Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study. *Lancet Oncol* 2017;18:1348-1359. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28802802>.
122. Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. *Dis Colon Rectum* 1974;17:354-356. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/4830803>.
123. Cummings BJ, Keane TJ, O'Sullivan B, et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. *Int J Radiat Oncol Biol Phys* 1991;21:1115-1125. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1938508>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

124. Papillon J, Chassard JL. Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients. Dis Colon Rectum 1992;35:422-429. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1568392>.

125. Czito BG, Willett CG. Current management of anal canal cancer. Curr Oncol Rep 2009;11:186-192. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19336010>.

126. Glynne-Jones R, Lim F. Anal cancer: an examination of radiotherapy strategies. Int J Radiat Oncol Biol Phys 2011;79:1290-1301. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21414513>.

127. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Coordinating Committee on Cancer Research. Lancet 1996;348:1049-1054. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8874455>.

128. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010;102:1123-1128. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20354531>.

129. Talwar G, Daniel R, McKechnie T, et al. Radiotherapy alone versus chemoradiotherapy for stage I anal squamous cell carcinoma: a systematic review and meta-analysis. Int J Colorectal Dis 2021;36:1111-1122. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33486535>.

130. Buckstein M, Arens Y, Wisnivesky J, et al. A Population-Based Cohort Analysis of Chemoradiation Versus Radiation Alone for Definitive Treatment of Stage I Anal Cancer in Older Patients. Dis Colon Rectum 2018;61:787-794. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29771796>.

131. Crehange G, Bosset M, Lorchel F, et al. Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum

2007;50:43-49. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17089083>.

132. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527-2539. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8823332>.

133. Murofushi KN, Itasaka S, Shimokawa M, et al. A phase II study of concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for squamous cell carcinoma of the anal canal (the JROSG 10-2 trial). J Radiat Res 2023;64:154-161. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/36280895>.

134. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579-588. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22503032>.

135. O'Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014;32:1927-1934. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24799484>.

136. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012;23:1190-1197. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21896539>.

137. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-2704. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15987918>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

138. Glynne-Jones R, Meadows H, Wan S, et al. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. *Int J Radiat Oncol Biol Phys* 2008;72:119-126. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18472366>.

139. Goodman K, Rothenstein D, Lajhem C, et al. Capecitabine plus mitomycin in patients undergoing definitive chemoradiation for anal squamous cell carcinoma. *Int J Radiat Oncol Biol Phys* 2014;90:S32–S33. Available at: [http://www.redjournal.org/article/S0360-3016\(14\)00792-5/fulltext](http://www.redjournal.org/article/S0360-3016(14)00792-5/fulltext).

140. Meulendijks D, Dewit L, Tomaso NB, et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. *Br J Cancer* 2014;111:1726-1733. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25167226>.

141. Thind G, Johal B, Follwell M, Kennecke HF. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma. *Radiat Oncol* 2014;9:124. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24885554>.

142. Oliveira SC, Moniz CM, Riechelmann R, et al. Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. *J Gastrointest Cancer* 2016;47:75-81. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26691173>.

143. James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. *Lancet Oncol* 2013;14:516-524. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23578724>.

144. Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. *J Clin Oncol*

2012;30:4344-4351. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23150707>.

145. Eng C, Crane CH, Rodriguez-Bigas MA. Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal? *Nat Clin Pract Gastroenterol Hepatol* 2009;6:16-17. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19047998>.

146. Abbas A, Yang G, Fakhri M. Management of anal cancer in 2010. Part 2: current treatment standards and future directions. *Oncology (Williston Park)* 2010;24:417-424. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20480740>.

147. Peiffert D, Tournier-Rangear L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. *J Clin Oncol* 2012;30:1941-1948. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22529257>.

148. Spithoff K, Cummings B, Jonker D, et al. Chemoradiotherapy for squamous cell cancer of the anal canal: a systematic review. *Clin Oncol (R Coll Radiol)* 2014;26:473-487. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24721444>.

149. Moureau-Zabotto L, Viret F, Giovaninni M, et al. Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 anal carcinoma? *J Surg Oncol* 2011;104:66-71. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21240983>.

150. Sebag-Montefiore D, Meadows HM, Cunningham D, et al. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. *Radiother Oncol* 2012;104:155-160. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22857859>.

151. Eng C, Jacome AA, Das P, et al. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. *Clin Colorectal*



NCCN Guidelines Version 4.2025

Anal Carcinoma

Cancer 2019;18:301-306. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/31350201>.

152. ClinicalTrials.gov. Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIb Anal Cancer. 2025. Available at: <https://clinicaltrials.gov/ct2/show/NCT03233711>. Accessed May 28, 2025.

153. U.S. Food & Drug Administration. Prescribing Information for cetuximab injection, for intravenous use. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf. Accessed May 28, 2025.

154. Van Damme N, Deron P, Van Roy N, et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 2010;10:189. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20459770>.

155. Zampino MG, Magni E, Sonzogni A, Renne G. K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol 2009;65:197-199. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19727729>.

156. Garg MK, Zhao F, Sparano JA, et al. Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial (E3205). J Clin Oncol 2017;35:718-726. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28068178>.

157. Sparano JA, Lee JY, Palefsky J, et al. Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS Malignancy Consortium trial. J Clin Oncol 2017;35:727-733. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27937092>.

158. Olivatto LO, Vieira FM, Pereira BV, et al. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer

2013;119:2973-2980. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23674135>.

159. Deutsch E, Lemanski C, Pignon JP, et al. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol 2013;24:2834-2838. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24026540>.

160. Levy A, Azria D, Pignon JP, et al. Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. Radiother Oncol 2015;114:415-416. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25769380>.

161. Holliday EB, Morris VK, Johnson B, et al. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist 2022;27:40-47. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35305097>.

162. Wallington DG, Holliday EB. Preparing patients for sexual dysfunction after radiation for anorectal cancers: a systematic review. Pract Radiat Oncol 2021;11:193-201. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32777386>.

163. Ortholan C, Ramaioli A, Peiffert D, et al. Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:479-485. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15890590>.

164. Ferrigno R, Nakamura RA, Dos Santos Novaes PER, et al. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys 2005;61:1136-1142. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15752894>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

165. Huang K, Haas-Kogan D, Weinberg V, Krieg R. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. *World J Gastroenterol* 2007;13:895-900. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17352019>.

166. John M, Pajak T, Flam M, et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. *Cancer J Sci Am* 1996;2:205-211. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9166533>.

167. ClinicalTrials.gov. Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study. 2025. Available at: <https://clinicaltrials.gov/ct2/show/NCT04166318>. Accessed May 28, 2025.

168. Konski A, Garcia M, Jr., John M, et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. *Int J Radiat Oncol Biol Phys* 2008;72:114-118. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18472363>.

169. Glynne-Jones R, Meadows HM, Lopes A, et al. Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial. *Ann Oncol* 2020;31:1376-1385. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32619648>.

170. Ben-Josef E, Moughan J, Ajani JA, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. *J Clin Oncol* 2010;28:5061-5066. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20956625>.

171. Graf R, Wust P, Hildebrandt B, et al. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. *Oncology* 2003;65:14-22. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12837978>.

172. Roohipour R, Patil S, Goodman KA, et al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. *Dis Colon*

Rectum 2008;51:147-153. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18180997>.

173. Allal AS, Sprangers MA, Laurencet F, et al. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. *Br J Cancer* 1999;80:1588-1594. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10408404>.

174. de Bree E, van Ruth S, Dewit LGH, Zoetmulder FAN. High risk of colostomy with primary radiotherapy for anal cancer. *Ann Surg Oncol* 2007;14:100-108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17066231>.

175. Baxter NN, Habermann EB, Tepper JE, et al. Risk of pelvic fractures in older women following pelvic irradiation. *JAMA* 2005;294:2587-2593. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16304072>.

176. Call JA, Prendergast BM, Jensen LG, et al. Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study. *Am J Clin Oncol* 2014;39:8-12. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24401669>.

177. Chen YJ, Liu A, Tsai PT, et al. Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. *Int J Radiat Oncol Biol Phys* 2005;63:274-281. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16111597>.

178. Chuong MD, Freilich JM, Hoffer SE, et al. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. *Gastrointest Cancer Res* 2013;6:39-45. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23745158>.

179. DeFoe SG, Beriwal S, Jones H, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. *Clin Oncol (R Coll Radiol)* 2012;24:424-431. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22075444>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

180. Franco P, Mistrangelo M, Arcadipane F, et al. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series. *Cancer Invest* 2015;33:259-266. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25950188>.

181. Kachnic LA, Tsai HK, Coen JJ, et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. *Int J Radiat Oncol Biol Phys* 2012;82:153-158. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21095071>.

182. Lin A, Ben-Josef E. Intensity-modulated radiation therapy for the treatment of anal cancer. *Clin Colorectal Cancer* 2007;6:716-719. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18039425>.

183. Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. *Int J Radiat Oncol Biol Phys* 2005;63:354-361. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16168830>.

184. Mitchell MP, Abboud M, Eng C, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. *Am J Clin Oncol* 2014;37:461-466. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23466576>.

185. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. *J Clin Oncol* 2007;25:4581-4586. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17925552>.

186. Yates A, Carroll S, Kneebone A, et al. Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions. *Clin Oncol (R Coll Radiol)* 2015;27:700-707. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26382849>.

187. Bazan JG, Hara W, Hsu A, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell

carcinoma of the anal canal. *Cancer* 2011;117:3342-3351. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21287530>.

188. Dasgupta T, Rothenstein D, Chou JF, et al. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. *Radiother Oncol* 2013;107:189-194. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23692961>.

189. Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. *Int J Radiat Oncol Biol Phys* 2013;86:27-33. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23154075>.

190. Kachnic LA, Winter KA, Myerson RJ, et al. Long-term outcomes of NRG Oncology/RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-c for the reduction of acute morbidity in anal canal cancer. *Int J Radiat Oncol Biol Phys* 2022;112:146-157. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34400269>.

191. Mitra D, Hong TS, Horick N, et al. Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529. *Adv Radiat Oncol* 2017;2:110-117. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28740921>.

192. Chin AL, Pollom EL, Qian Y, et al. Impact of intensity-modulated radiotherapy on health care costs of patients with anal squamous cell carcinoma. *J Oncol Pract* 2017;13:e992-e1001. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29035618>.

193. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. *Int J Radiat Oncol Biol Phys* 2009;74:824-830. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19117696>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

194. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012;136:1266-1297. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22742517>.

195. Cappello C, Cuming T, Bowring J, et al. High-Resolution Anoscopy Surveillance After Anal Squamous Cell Carcinoma: High-Grade Squamous Intraepithelial Lesion Detection and Treatment May Influence Local Recurrence. Dis Colon Rectum 2020;63:1363-1371. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32969879>.

196. Arana R, Flejou JF, Si-Mohamed A, et al. Clinicopathological and virological characteristics of superficially invasive squamous-cell carcinoma of the anus. Colorectal Dis 2015;17:965-972. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25784158>.

197. Chai CY, Tran Cao HS, Awad S, Massarweh NN. Management of stage I squamous cell carcinoma of the anal canal. JAMA Surg 2018;153:209-215. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29049547>.

198. Duncan KC, Chan KJ, Chiu CG, et al. HAART slows progression to anal cancer in HIV-infected MSM. AIDS 2015;29:305-311. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25686679>.

199. Grew D, Bitterman D, Leichman CG, et al. HIV infection is associated with poor outcomes for patients with anal cancer in the highly active antiretroviral therapy era. Dis Colon Rectum 2015;58:1130-1136. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26544809>.

200. Oehler-Janne C, Huguet F, Provencher S, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008;26:2550-2557. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18427149>.

201. Camandaroba MPG, de Araujo RLC, Silva VSE, et al. Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis. J Gastrointest Oncol 2019;10:48-60. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30788159>.

202. Alfa-Wali M, Dalla Pria A, Nelson M, et al. Surgical excision alone for stage T1 anal verge cancers in people living with HIV. Eur J Surg Oncol 2016;42:813-816. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27012999>.

203. Bryant AK, Huynh-Le MP, Simpson DR, et al. Association of HIV status with outcomes of anal squamous cell carcinoma in the era of highly active antiretroviral therapy. JAMA Oncol 2018;4:120-122. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28975226>.

204. Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 2008;26:474-479. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18202423>.

205. Leeds IL, Alturki H, Canner JK, et al. Outcomes of abdominoperineal resection for management of anal cancer in HIV-positive patients: a national case review. World J Surg Oncol 2016;14:208. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27495294>.

206. Martin D, Balermipas P, Fokas E, et al. Are there HIV-specific differences for anal cancer patients treated with standard chemoradiotherapy in the era of combined antiretroviral therapy? Clin Oncol (R Coll Radiol) 2017;29:248-255. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28049602>.

207. Pappou EP, Magruder JT, Fu T, et al. Prognostic and predictive clinicopathologic factors of squamous anal canal cancer in HIV-positive and HIV-negative patients: does HAART influence outcomes? World J Surg 2018;42:876-883. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28948325>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

208. Seo Y, Kinsella MT, Reynolds HL, et al. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. *Int J Radiat Oncol Biol Phys* 2009;75:143-149. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19203845>.
209. White EC, Khodayari B, Erickson KT, et al. Comparison of toxicity and treatment outcomes in HIV-positive versus HIV-negative patients with squamous cell carcinoma of the anal canal. *Am J Clin Oncol* 2014;40:386-392. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25513996>.
210. Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated cancer-specific mortality among HIV-infected patients in the United States. *J Clin Oncol* 2015;33:2376-2383. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26077242>.
211. Holliday EB, Lester SC, Harmsen WS, et al. Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. *Int J Radiat Oncol Biol Phys* 2018;102:102-108. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29907489>.
212. Faivre C, Rougier P, Ducreux M, et al. [5-fluorouracil and cisplatin combination chemotherapy for metastatic squamous-cell anal cancer]. *Bull Cancer* 1999;86:861-865. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10572237>.
213. Kole AJ, Stahl JM, Park HS, et al. Predictors of nonadherence to NCCN guideline recommendations for the management of stage I anal canal cancer. *J Natl Compr Canc Netw* 2017;15:355-362. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28275036>.
214. Geltzeiler CB, Tsikitis VL, Kim JS, et al. Variation in the use of chemoradiotherapy for stage II and III anal cancer: analysis of the National Cancer Data Base. *Ann Surg Oncol* 2016;23:3934-3940. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27444107>.
215. Glynne-Jones R, Sebag-Montefiore D, Meadows HM, et al. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. *Lancet Oncol* 2017;18:347-356. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28209296>.
216. Schiller DE, Cummings BJ, Rai S, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. *Ann Surg Oncol* 2007;14:2780-2789. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17638059>.
217. Mullen JT, Rodriguez-Bigas MA, Chang GJ, et al. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. *Ann Surg Oncol* 2007;14:478-483. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17103253>.
218. Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. *Int J Radiat Oncol Biol Phys* 2007;68:794-800. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17379452>.
219. Sunesen KG, Norgaard M, Lundby L, et al. Cause-specific colostomy rates after radiotherapy for anal cancer: a danish multicentre cohort study. *J Clin Oncol* 2011;29:3535-3540. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21825256>.
220. Ozsahin M, Santa Cruz O, Bouchaab H, et al. Definitive organ-sparing treatment of anal canal cancer: can we afford to question it? *J Clin Oncol* 2012;30:673-674; author reply 674-675. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22278906>.
221. Allal AS, Laurencet FM, Reymond MA, et al. Effectiveness of surgical salvage therapy for patients with locally uncontrolled anal carcinoma after sphincter-conserving treatment. *Cancer* 1999;86:405-409. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10430247>.
222. Delhorme JB, Severac F, Waissi W, et al. Surgery is an effective option after failure of chemoradiation in cancers of the anal canal and



NCCN Guidelines Version 4.2025

Anal Carcinoma

anal margin. Oncology 2017;93:183-190. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/28571009>.

223. Ellenhorn JD, Enker WE, Quan SH. Salvage abdominoperineal resection following combined chemotherapy and radiotherapy for epidermoid carcinoma of the anus. Ann Surg Oncol 1994;1:105-110. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7834434>.

224. Nilsson PJ, Svensson C, Goldman S, Glimelius B. Salvage abdominoperineal resection in anal epidermoid cancer. Br J Surg 2002;89:1425-1429. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12390386>.

225. Ko G, Sarkaria A, Merchant SJ, et al. A systematic review of outcomes after salvage abdominoperineal resection for persistent or recurrent anal squamous cell cancer. Colorectal Dis 2019;21:632-650. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30689272>.

226. Wright JL, Gollub MJ, Weiser MR, et al. Surgery and high-dose-rate intraoperative radiation therapy for recurrent squamous-cell carcinoma of the anal canal. Dis Colon Rectum 2011;54:1090-1097. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21825888>.

227. Chessin DB, Hartley J, Cohen AM, et al. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol 2005;12:104-110. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15827789>.

228. Devulapalli C, Jia Wei AT, DiBiagio JR, et al. Primary versus flap closure of perineal defects following oncologic resection: A systematic review and meta-analysis. Plast Reconstr Surg 2016;137:1602-1613. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26796372>.

229. Lefevre JH, Corte H, Tiret E, et al. Abdominoperineal resection for squamous cell anal carcinoma: survival and risk factors for recurrence. Ann Surg Oncol 2012;19:4186-4192. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22825769>.

230. Harris DA, Williamson J, Davies M, et al. Outcome of salvage surgery for anal squamous cell carcinoma. Colorectal Dis 2013;15:968-973. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23522325>.

231. Cummings BJ. Metastatic anal cancer: the search for cure. Onkologie 2006;29:5-6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16514247>.

232. Wang Y, Yu X, Zhao N, et al. Definitive Pelvic Radiotherapy and Survival of Patients With Newly Diagnosed Metastatic Anal Cancer. J Natl Compr Canc Netw 2019;17:29-37. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30659127>.

233. Engstrand J, Abreu de Carvalho LF, Aghayan D, et al. Liver resection and ablation for squamous cell carcinoma liver metastases. BJS Open 2021;5. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34426830>.

234. Rao S, Samalin-Scalzi E, Evesque L, et al. LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo) [abstract]. Ann Oncol 2024;35:S1217. Available at: <https://doi.org/10.1016/j.annonc.2024.08.2262>.

235. ClinicalTrials.gov. EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients. 2025. Available at: <https://clinicaltrials.gov/ct2/show/NCT04444921>. Accessed May 28, 2025.

236. Rao S, Sclafani F, Eng C, et al. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAACT. J Clin Oncol 2020;38:2510-2518. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32530769>.

237. Ajani JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver



NCCN Guidelines Version 4.2025

Anal Carcinoma

metastases from carcinoma of the anal canal. Am J Med 1989;87:221-224. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2527006>.

238. Eng C, Chang GJ, You YN, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget 2014;5:11133-11142. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25373735>.

239. Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol 1993;16:536-540. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8256774>.

240. Kim R, Byer J, Fulp WJ, et al. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology 2014;87:125-132. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25012155>.

241. Sclafani F, Morano F, Cunningham D, et al. Platinum-fluoropyrimidine and paclitaxel-based chemotherapy in the treatment of advanced anal cancer patients. Oncologist 2017;22:402-408. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28209745>.

242. Mondaca S, Chatila WK, Bates D, et al. FOLFOX Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer. Clin Colorectal Cancer 2019;18:e39-e52. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30316684>.

243. Matsunaga M, Miwa K, Oka Y, et al. Successful treatment of metastatic anal canal adenocarcinoma with mFOLFOX6 + bevacizumab. Case Rep Oncol 2016;9:249-254. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27239180>.

244. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol 2006;24:394-400. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16421419>.

245. Kim S, Francois E, Andre T, et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Lancet Oncol 2018;19:1094-1106. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30042063>.

246. Kim S, Jary M, Mansi L, et al. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol 2013;24:3045-3050. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24114858>.

247. Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:446-453. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28223062>.

248. Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017;28:1036-1041. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28453692>.

249. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020;38:1-10. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31682550>.

250. Marabelle A, Cassier PA, Fakih M, et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol 2022;7:446-454. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35114169>.

251. Rao S, Anandappa G, Capdevila J, et al. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202). ESMO Open 2022;7:100529. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35816951>.



NCCN Guidelines Version 4.2025

Anal Carcinoma

252. ClinicalTrials.gov. Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer. 2025. Available at: <https://clinicaltrials.gov/ct2/show/NCT02314169>. Accessed May 28, 2025.

253. Salem ME, Puccini A, Grothey A, et al. Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers. *Mol Cancer Res* 2018;16:805-812. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29523759>.

254. Hewitt M, Greenfield S, Stovall E, eds. From Cancer Patient to Cancer Survivor: Lost in Transition. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council: National Academy of Sciences; 2006. Available at: <http://www.nap.edu/catalog/11468.html>.

255. El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society Colorectal Cancer Survivorship Care Guidelines. *CA Cancer J Clin* 2015;65:428-455. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26348643>.

256. Bentzen AG, Guren MG, Vonen B, et al. Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort. *Radiother Oncol* 2013;108:55-60. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23891095>.

257. Mirabeau-Beale K, Hong TS, Niemierko A, et al. Clinical and treatment factors associated with vaginal stenosis after definitive chemoradiation for anal canal cancer. *Pract Radiat Oncol* 2015;5:e113-118. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25424587>.

258. Sunesen KG, Norgaard M, Lundby L, et al. Long-term anorectal, urinary and sexual dysfunction causing distress after radiotherapy for anal cancer: a Danish multicentre cross-sectional questionnaire study. *Colorectal Dis* 2015;17:O230-239. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26218674>.

259. Knowles G, Haigh R, McLean C, Phillips H. Late effects and quality of life after chemo-radiation for the treatment of anal cancer. *Eur J Oncol Nurs* 2015;19:479-485. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25911268>.

260. Sterner A, Derwinger K, Staff C, et al. Quality of life in patients treated for anal carcinoma-a systematic literature review. *Int J Colorectal Dis* 2019;34:1517-1528. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31324957>.

261. Jephcott CR, Paltiel C, Hay J. Quality of life after non-surgical treatment of anal carcinoma: a case control study of long-term survivors. *Clin Oncol (R Coll Radiol)* 2004;16:530-535. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15630846>.

262. Badin S, Iqbal A, Sikder M, Chang VT. Persistent pain in anal cancer survivors. *J Cancer Surviv* 2008;2:79-83. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18648976>.